HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
 Masonic Cancer Center  
University of Minnesota  
  
Nivolumab, Oral Cyclophosphamide, and N-803 for Relapsed/Refractory Acute 
Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndrome (MDS)  
  
HM2017- 33  
CPRC # 2017LS116  
IND 138758  
BMS protocol number CA209-9WK  
  
Principal Investigator/IND Sponsor:  
Fiona He, MD  
  
Co-Investigators:  
Mukta Arora, MD  
Veronika Bachanova, MD, PhD  
Claudio Brunstein, MD, PhD  
Craig Eckfeldt, MD, PhD   
Najla El Jurdi, MD  
Michael Linden, MD, PhD*  
Joseph Maakaron, MD  
Jeffrey Miller, MD  
Armin Rashidi MD, PhD   
Zohar Sachs, MD, PhD  
Erica Warlick, MD   
Daniel J. Weisdorf, MD  
  
*will not consent study participants  
  
Biostatistician:  
Qing Cao, MS  
  
  
  
Version Date:  
May 12, 2021   
  
Confidential  
  
Revision History  
  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
May 
12, 2021  Page 2 of 79  CPRC #2017LS116  Revision 
#  Version 
Date  Detail of Changes  Consent 
change?  
(Y/N)  
  10/03/2017  Original version for CPRC and BMS (earlier version sent)  n/a  
  11/01/2017  In response to CPRC stips:   
Expand nivolumab background information in Section 2.3  and Section 2.4  
(new)    
Add wording to Section 6.2  regarding use of hydroxurea and 
immunosuppression during the study treatment.   
Other edits:   
Cover page - update Co- I’s   
Section 4.2.1  – clarify negative pregnancy test with 7 days of study 
administration   
Section 13  and Section 14.2  – provide more detail pertaining to study 
endpoints   
Section 14.3  – expand definition of evaluable   
Other minor edits and updates  n/a  
  02/23/2018  Original version to the IRB and FDA:  
To align versions approved by [CONTACT_675123] (no changes from BMS affecting the 11/01/2017 vers ion approved by 
[CONTACT_675124])   
Update in protocol template language:  
• Update Section 5  Patient Registration/Study Enrollment to current 
template language  
• Section 12.3  – delete wording about submitting copy of IRB continuing 
review to CPRC  
• Replace CTCAE v 4.03 with v 5.0   
• Replace study coordinator with newer designation of Primary Clinical 
Research Coordinator (PCRC)  
• Add co-investigators   
Other minor edits and clarifications throughout.  n/a  
  03/20/2018  In response to FDA’s potential hold and non -hold comments:  
• Synopsis , schema , Section 3  and Section 6.3  – clarify and make 
consistent that an increase in absolute blast count is ≥ 25% in 
peripheral blood or bone marrow from baseline is criteria for s toppi[INVESTIGATOR_675100]  
• Synopsis , Section 4.1.2  and Appendix I - Add risk score of >4.5 to the 
definition of higher risk MDS, separate relapsed AML and MDS 
eligibility requirements  
• Synopsis , Section 4.1.4  and Appendix I  – add bilirubin ≤ [ADDRESS_912416] and ALT results (previously o r)  
• Section 3 , Section 11.2  and Section 14.4  – add selected Grade 3 
nonhematologic events that result in the permanent discontinuat ion of 
nivolumab (diarrhea, colitis, pneumonitis, transaminitis, myoca rditis, 
adrenal insufficiency)  
• Section 6.1.1  – clarify nivolumab will be administered in the outpatient 
setting, add monitoring language.  
• Add IND number to the  title page   yes  
1  05/17/2018  • Per BMS for patient safety - Nivolumab may induce graft versus host 
disease in patients who have had a prior allo-HSCT. To reduc e this risk, 
patients who have had a prior alloHSCT will receive a lower dose of 
nivolumab (1 mg/kg instead of 3 mg/kg).  
• Increase research sample blood volume as an insufficient amount  was 
originally written into the protocol   
• Minor edits to match current protocol template  Yes  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
May 
12, 2021  Page 3 of 79  CPRC #2017LS116  2  09/13/2018  • Updated Principal Investigator/IND Sponsor  to Fiona He, MD  Yes  
 
Revision 
#  Version 
Date  Detail of Changes  Consent 
change?  
(Y/N)  
  • Section 4.1.2  & Eligibility checklis t: Updated eligibility criteria (disease 
status)  
• Minor clarification of research blood draw procedure  
• Section 14.4  updated sample size  
• Protocol synopsis: Updated for clarification including monthly peripheral 
blood blast count disease evaluation   
• Section 1.3  correlative objectives added neo-antigen identification on 
blasts   
• Section 8.1  bone marrow biopsy evaluations, changed screening bone 
marrow biopsy to within 21 days of study registration, and t hat bone 
marrow biopsies may be omitted if not medically safe to perform    
3  03/26/2019  • Removed bone marrow biopsy response assessment from final 
treatment visit  
• Cyclophosphamide will now be provided by [CONTACT_20444]  
• Updated study committee  to remove Drs Cooley & Ustun  Yes  
4  12/04/2019  • Updated study committee  to add Najla El Jurdi and Joseph Maakaron   
• Schema , Synopsis , Section 1 , , Section 3 , Section 6.1 , Section 7.3 , 
Section 10.3 ,Section 14.3 , Appendix V , Appendix VI :  Added SC N- 803 
once every 3 weeks in treatment schema, changed Nivolumab do sing 
frequency to once every 3 weeks   
• Schema , Section 3 , Section 5.2 , Section 6 , Section 8.1 , Section 8.2 , 
Section 14.1 : Changed total number of cycles from 4 to 5 (each cycle  
defined as 3 weeks instead of 4 weeks)   
• Synopsis , Section 1.1 , Section 3 , Section 6.4 , Section 13 , Section 14 : 
Changed bone marrow evaluation schedule from D30 and D90 to  D21 
and D42   
• Section 2.6 , Section 2.8 : Added background information for N- 803  
• Section 8.2 : Added research blood draw at C1D8, C1D15, C2D1, C2D 8, 
C2D15, C3D1, C4D1, C5D1, end of treatment visit    
• Synopsis , Section 4.1 , Section 8.2: Added disease eligibility criteria of 
extramedullary leukemia that is biopsy-confirmed in absence of b one 
marrow involvement; added CT or PET-scan for disease restag ing   
• Section 4.1 : Added to inclusion criteria: Ability to be off prednisone and 
other immunosuppressive drugs (>10 mg daily prednisone equ ivalent) for 
at least 14 days prior to and while receiving N-803. Inhaled  or topi[INVESTIGATOR_28709], and adrenal replacement steroid doses < 10 mg d aily 
prednisone equivalent, are permitted in the absence of ac tive 
autoimmune disease  
• Section 4.2 : Added prior N-[ADDRESS_912417] within 30 days as exclusion   
• Added Appendix V  and Appendix VI   
• Section 6.1 , Section 7 , Section 11 , and Section 14.4  reverted protocol 
back to CTCAE v 4.03 in order to match protocol build in Onco re  
• Section 1.1, Section 14.1: Changed timepoint for primary e ndpoint of 
ORR to day 42  Yes  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
May 
12, 2021  Page 4 of 79  CPRC #2017LS116  5  06/08/2020  Per FDA Stipulations:  
• Synopsis , Schema , Section 3 , Section 5.2 , Section 6.1 , Section 
14.1: Clarified that original treatments as closed Arms 1 and 2, 
treatment with N803 will be called Arms 3 and 4  
• Synopsis , Section 3 ; Clarified that Day 42 BMBX will be used to 
help determine additional cycles  
• Synopsis , Section 1.3 : added correlative objective to assess Tcell 
infiltration through immunohistochemical testing in the bone 
marrow  
• Synopsis , Section 4.1 : clarified eligibility for relapsed MDS  
• Synopsis , section 4.2 : added exclusion for allo HSCT receiving 
calcineurin inhibitor within 4 weeks  
• Section 6.1 : updated eligibility for additional cycles (moved 
information previously in section 6.1.5 )  
• Section 6.1.5 : updated dose administration guidelines for N803  
• Section 6.2 : Updated GVHD management guidelines  No  
Revision 
#  Version 
Date  Detail of Changes  Consent 
change?  
(Y/N)  
  • Section 6.3 : updated definition of disease progression  
• Section 11.2 , section 14.4 : updated stoppi[INVESTIGATOR_675101]:  
• Section 3  – Added N803 as part of endpoint  Minor 
edits and clarifications:  
• Section 7.1,  section 8.1  – added “N -803”   
• Section 8.2 : updated research tests performed on lab 
samples  
• Throughout protocol updated internal HTML and 
section links   
6  9/18/2020  Per FDA Stipulations:  
Synopsis , Section 1.1 , Section 3.0,  Section 5.2,   Section 14.1 - Removed 
stage II from trial design  
Synopsis , Section 1.2 , Section 14.1  - defined response rate in secondary 
objectives  
Synopsis , Section 3.0 ,  Section 14.1 - updated accrual goal  
Section 3.0 , Section 11.2,  Section 14.4 - Updated stoppi[INVESTIGATOR_675102] 6.1  – clarified eligibility to begin additional treatment courses  
Section 6.2  – Updated study management in the case of new onset GVHD  
  
Additional Edits:  
Section 7.[ADDRESS_912418] Investigator Brochures  
  Yes  
7  04/28/2021  Synopsis , Schema , Section 3.0 , Section 5.2 , Section 14.3,  Section 14.4 , 
number of patients changed from 24 to 20 – Rationale: improve feasibility 
of recruitment while maintaining goals for statistical power  
Synopsis , section 1.3 , Section 8.2 , added and clarified correlative studies 
Rationale: add immune-related gene expression profiling of bo ne marrow 
to evaluate other pathways that may confer sensitivity o r resistance to 
therapy  
Section 8.2  added bone marrow sample. Rationale: for RNA gene 
expression studies  
Section 13.0 , Section 14.1  changed primary endpoint to dose 
determination, moved original primary endpoint to secondary. Rationale: 
prior amendment removed stage II from study design. Primary end point 
changed to reflect dose finding rather than efficacy.  Yes  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
May 
12, 2021  Page 5 of 79  CPRC #2017LS116  7A  05/12/2021  Synopsis , Schema  – corrected number of patients. Rationale – error 
correction (number of patients was amended in previous version)  No  
  
  
PI/IND Sponsor Contact [CONTACT_7171]: 
Fiona He, MD  
Assistant Professor of Medicine 
Division of Hematology, Oncology 
and Transplantation MMC 480, [ADDRESS_912419] S.E.  
Minneapolis, MN [ZIP_CODE]  
([PHONE_13998] (phone) 
([PHONE_13999] (fax)  
[EMAIL_12901] Table of 
Contents  
  
Table of Key Abbreviations ........................................................................................................................................  7 
Protocol Synopsis ........................................................................................................................................................  8 
Study Schema ............................................................................................................................................................  11 
1  Objectives ..............................................................................................................................................................  12 
1.1  Primary Objective ..........................................................................................................................................  12 
1.2  Secondary Objectives .....................................................................................................................................  12 
1.3  Correlative Objectives ....................................................................................................................................  12 
2  Background and Rationale ....................................................................................................................................  12 
2.1  High-risk AML and MDS ..............................................................................................................................  12 
2.2  Defective Leukemic Immunosurveillance in AML and MDS .......................................................................  13 
2.3  PD-1/PD-L1 Pathway in Malignancies ..........................................................................................................  13 
2.4  PD-1/PD-L1 Pathway in AML and MDS ......................................................................................................  [ADDRESS_912420] ................................................................ . 26 
6.3  Supportive Care ..............................................................................................................................................  27 
6.4  Duration of Study Treatment ..........................................................................................................................  27 
6.5  Duration of Study Participation ......................................................................................................................  27 
7  Management of Selected Toxicity .........................................................................................................................  28 
7.1  Nivolumab and N- 803 ....................................................................................................................................  28 
7.2  Oral Cyclophosphamide ................................................................................................................................ . 38 
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
May 
12, 2021  Page 6 of 79  CPRC #2017LS116  7.3  N-803 .............................................................................................................................................................  39 
8  Schedule of Tests and Procedures .........................................................................................................................  39 
8.1 Required Clinical Care Evaluations ................................................................................................................  40 
8.2 Research Related Evaluations .........................................................................................................................  41 
9  Disease Assessment Criteria ................................................................................................................................ . 42 
10  Drug Formulation, Availability and Preparation ................................................................................................ . 42 
10.1 Nivolumab .....................................................................................................................................................  42 
10.2 Low Dose Cyclophosphamide .......................................................................................................................  44 
10.3  N-803 Formulation, Supply, and Potential Toxicity ....................................................................................  44 
10.4  N-803 in Combination with Nivolumab .......................................................................................................  48 
11  Adverse Event Monitoring, Documentation and Reporting ................................................................................  48 
11.1 Adverse Event Terminology .........................................................................................................................  49 
11.2 Adverse Event Documentation ......................................................................................................................  50 
11.3 Required Reporting FDA, IRB, and Masonic C ancer Center’s SAE Coordinator  ........................................  52 
11.4  Additional BMS Requirements for Nivolumab ............................................................................................  53 
12  Study Data Collection and Monitoring ...............................................................................................................  53 
12.1  Data Management ........................................................................................................................................  53 
12.2 Case Report Forms ........................................................................................................................................  54 
12.3 Data and Safety Monitoring Plan (DSMP) ....................................................................................................  [ADDRESS_912421] Retention ..........................................................................................................................................  55 
13  Endpoints ............................................................................................................................................................  56 
14  Statistical Considerations ....................................................................................................................................  56 
14.1  Study Design ................................................................................................................................................  56 
14.2  Data Analysis Plan .......................................................................................................................................  57 
14.3  Sample Size Justification .............................................................................................................................  58 
14.4  Early Study Stoppi[INVESTIGATOR_675103] ..........................................................................................................  59 
15  Ethical and Regulatory Considerations ...............................................................................................................  59 
15.1  Good Clinical Practice ................................................................................................................................ . 59 
15.2  Ethical Considerations ..................................................................................................................................  59 
15.3  Informed Consent .........................................................................................................................................  60 
16  References ...........................................................................................................................................................  60 
Appendix I – ECOG Performance Status ..................................................................................................................  67 
Appendix II – Revised International Prognostic Scoring System .............................................................................  68 
Appendix III – Response Criteria For MDS and AML .............................................................................................  69 
Appendix IV – GVHD Grading Scales .....................................................................................................................  69 
Appendix V - N-803 Targeted Toxicity Worksheet ..................................................................................................  73 
Appendix VI – N-803 Injection Site Reactions Diary ...............................................................................................  75 
 
  
  
  
     
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
May 
12, 2021  Page 7 of 79  CPRC #2017LS116  Table of Key Abbreviations  
  
ALT  alanine aminotransferase (aka SGPT)  
alloHSCT  allogeneic hematopoietic stem cell transplant  
AML  acute myeloid leukemia  
AST  aspartate aminotransferase (aka SGOT)  
BM  bone marrow  
CNS  central nervous system  
CR  complete remission  
CRi  complete remission with incomplete blood count 
recovery  
CRp  complete remission with incomplete platelet count 
recovery  
CTCAE  
v4.[ADDRESS_912422]  hematopoietic cell transplant  
HI  hematologic improvement   
IDO  indolamine 2,3 dioxygenase  
IPSS  International Prognostic Scoring System  
irAE  immune related adverse event  
IV  intravenous  
MDS  myelodysplastic syndrome  
MDSC  myeloid derived suppressor cells  
NK  natural killer  
OR  objective response  
ORR  overall response rate   
OS  overall survival  
PO  per os   
PR  partial remission  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
May 
12, 2021  Page 8 of 79  CPRC #2017LS116  PFS  progression-free survival  
SOC  standard of care  
WOCBP  women of childbearing potential  
    
Protocol Synopsis  
Nivolumab, Oral Cyclophosphamide and N-803 for Relapsed/Refractory Acute 
Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndrome (MDS)  
  
Study 
Design:   This is a phase I trial of nivolumab, low dose cyclophosphamide (CTX) 
and N-803 when given in combination to patients with 
relapsed/refractory acute myeloid leukemia (AML) and higher-risk 
myelodysplastic syndrome (MDS) who are not eligible for or decline 
hematopoietic stem cell transplant. It includes a randomized pi[INVESTIGATOR_675104] 1. Arm 1 and Arm 2 previously randomized 
patients in 1:1 ratio to IV nivolumab 3 mg/kg every 2 weeks and oral 
cyclophosphamide 50 mg daily or IV nivolumab 3 mg/kg every 2 
weeks and oral cyclophosphamide 350 mg weekly. Arms 1 and 2 are 
now closed.    
  
20 patients enrolled in the study are randomized to either Arm 3 (CTX 
50mg PO daily + nivolumab IV and 10 ug/kg SC N-803 every 3 weeks) 
or Arm 4 (CTX 350 mg PO every 7 days + nivolumab IV  and 10 ug/kg 
SC N-803 every 3 weeks) with [ADDRESS_912423] count is 
<25% in peripheral blood or bone marrow from baseline at day [ADDRESS_912424] will proceed with further treatment with up to five 21-day 
courses.   
  
Continuous stoppi[INVESTIGATOR_675105]. If one arm is terminated by [CONTACT_675125][INVESTIGATOR_1877], all 
subsequent patients will be assigned to the other arm if it is not 
terminated by [CONTACT_675125][INVESTIGATOR_675106] 
20 patients.   
  
All patients receive nivolumab IV and SC N-803 every 3 weeks and 
oral cyclophosphamide (daily or weekly) as assigned for up to 5 
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
May 
12, 2021  Page 9 of 79  CPRC #2017LS116  treatment courses with each treatment course equal to [ADDRESS_912425] dose of study drug with 
follow-up for response and survival continuing through 2 years from 
beginning of treatment. For patients with clinical benefit after the 5 
treatment courses, additional therapy with the study drugs or other 
treatment may be offered.  
  
Primary  To identify the safety, immunological activity, and clinical benefit of  
Objective:  combination of nivolumab, N-803 and low-dose oral CTX when given in 
patients with relapsed/refractory AML and higher-risk MDS   
  
Secondary • To estimate objective response rate (ORR) at 42 days from  
Objectives:  treatment start. Response is defined as CR + CRi + CRp + PR in AML a nd 
CR/PR/hematologic improvement (HI) in MDS  
• To estimate progression-free survival (PFS) and overall survival 
(OS) at 6 months from treatment start  
Correlative  •  To evaluate level of immune activation in blood and bone  
Objectives :  marrow microenvironment by [CONTACT_675126] T-cells subsets, natural killer (NK) cells, 
myeloid derived suppressor cells (MDSC), and dendritic cells 
(DC) during treatment  
• To assess PD1/PD-L1 and TIM-3/galectin-9 interactions throug h 
quantified expression of PD-L1 and galectin-9 on leukemic 
blasts, galectin-9 in serum, PD-1 and TIM-3 on immune cells as 
biomarkers of response and potential mechanisms of resistance 
to treatment    
• To assess T-cell infiltration through immunohistochemical 
testing in the bone marrow   
• To evaluate immune and leukemia-related gene expression 
patterns in bone marrow aspi[INVESTIGATOR_675107]:   Primary (de novo) AML or higher-risk MDS with induction failure: No 
CR after 2 or more induction attempts with high dose chemothera py, 
hypomethylating agents, or other agents; No CR after 1 induction 
attempt and not eligible for a 2nd induction. Higher risk MDS defined 
as risk score > 4.5 based on the by [CONTACT_675127] (IPSS) criteria.     
  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
May 
12, 2021  Page 10 of 79   CPRC #2017LS116  Secondary AML (from antecedent hematologic malignancy or 
treatment-related): Not in CR after 1 or more cycles of chemotherapy   
  
Relapsed AML: Blasts ≥5% in bone marrow or peripheral blood after 
prior attainment of CR  or biopsy-proven extramedullary leukemia in 
absence of bone marrow involvement; relapse at any time, but 
currently ≥[ADDRESS_912426]  
  
Relapsed MDS: morphologic evidence of relapse or increase in blasts 
to ≥5% in bone marrow or peripheral blood after prior attainment of CR 
and not eligible for or decline intensive chemotherapy; relapse at any 
time but currently ≥[ADDRESS_912427]  
   
Key 
Inclusion 
Criteria:   • ≥18 years of age  
• ECOG status ≤ 2  
• ineligible for or declines allogenic hematopoietic transplantation  
• voluntary written consent   
• Adequate organ function as defined by [CONTACT_675128] > 500 cells/m3, serum 
creatinine ≤2 mg/dL, AST and ALT ≤ 5x ULN, Bilirubin ≤[ADDRESS_912428], 
no O 2 requirements on room air or requiring ≤2L O 2   
  
Key 
Exclusion 
Criteria:  • acute promyelocytic leukemia   
• pregnant or breastfeeding  
• prior allogeneic hematopoietic stem cell transplantation currently 
within 100 days (note patients with prior alloHSCT receive a 
reduced dose of nivolumab); they are eligible after that date  
• therapeutic immunosuppression within preceding 1 month  
• signs or symptoms of graft versus host disease   
• active pneumonitis or uncontrolled infection  
• active, uncontrolled autoimmune disease  
• chemotherapy within the previous 2 weeks  
• estimated life expectancy less than 28 days    
• Previously treated with N-803 (or “ALT -803”)  
• Cellular therapy product within 30 days   
• Allogeneic HSCT recipi[INVESTIGATOR_675108] 4 
weeks  
  
Accrual  
Objective:   20 patients randomized (50:50) to 1 of 2 treatment arms  
  
Enrollment: 1-2 patients per month  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
 Study Schema  
   
Arm 1 and Arm 2 previously randomized patients in 1:1 ratio to nivolumab 3 mg/kg every 2 
weeks and low dose cyclophosphamide 50 mg daily or 350 mg weekly and enrolled 12 
patients. Due to low response rates (no complete responses and only 2 patients with part ial 
response) and 4 patients receiving ≤1 cycle of treatment due to rapid disease progressi on, 
arms 1 and 2 are now closed.  Arms 3 and 4 are open and will add N-803 to the platfor m of 
nivolumab and low dose cyclophosphamide daily or weekly. All patients without prior history of  
allogeneic stem cell transplantation receive nivolumab 360 mg every 3 weeks, low dose 
cyclophosphamide (CTX) at assigned dose/schedule (daily versus weekly), and N- 803 
subcutaneously at 10 ug/kg every 3 weeks for up to 5 treatment courses. Patients with prior 
allogeneic stem cell transplantation will receive reduced dose of 180 mg nivolumab every 3 
weeks.  
  
One treatment course = 3 weeks  
  
Randomized Pi[INVESTIGATOR_16282] 20 patients randomized (1:1) to Arm 3 or Arm 4  
  
  
     
*Nivolumab dose is 360 mg unless the patient has had a prior alloge neic hematopoietic 
stem cell transplant (alloHSCT), in which case, the nivolumab dose is  
 180 mg.     

HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 12 of 79   CPRC #2017LS116  1 Objectives  
1.1 Primary Objective  
To identify the safety, immunological activity, and clinical benefit of combination 
of nivolumab, N-803 and low-dose oral CTX when given in patients with 
relapsed/refractory AML and higher-risk MDS   
  
  
1.2 Secondary Objectives  
• To estimate the overall response rate (ORR) at 42 days from treatment start.  
Response is defined as CR + CRi + CRp + PR in AML and  
CR/PR/hematologic improvement (HI) in MDS  
• To estimate progression-free survival (PFS) and overall survival (OS) at 6 
months from treatment start  
 1.3  Correlative Objectives  
• To evaluate level of immune activation in blood and bone marrow 
microenvironment by [CONTACT_675129] T-cell s 
subsets and natural killer (NK) cells during treatment  
• To assess PD1/PD-L1 and TIM-3/galectin-9 interactions through quantified  
expression of PD-L1 and galectin-9 on leukemic blasts, PD-1 and TIM-3 o n 
immune cells as biomarkers of response and potential mechanisms of 
resistance to treatment    
• To assess T-cell and NK cell infiltration through immunohistochemical 
testing in the bone marrow   
• To evaluate immune-related gene expression patterns in bone marrow 
aspi[INVESTIGATOR_675109]  
2 Background and Rationale  
 2.1  High-risk AML and MDS   
Acute myeloid leukemia is a disease with high mortality rate that is predominantly 
diagnosed in the elderly with median age of diagnosis of 67. Elderly pa tients are 
more likely to present with more aggressive disease, as evidenced by [CONTACT_675130].[ 1] Although 50-60% of patients with good performance status may 
achieve complete remission with cytotoxic chemotherapy (anthracycline and 
cytarabine in “7+3” regimen), 2 -year survival is poor at 15-20% due to high rates 
of relapse.[ 2] Salvage cytotoxic chemotherapy can induce objective response in 
25 to 40% of patients, but these remissions are not durable, likely due t o inability 
of chemotherapy to kill leukemic stem cells that persist. [ 3]   
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 13 of 79   CPRC #2017LS116  Higher-risk MDS, as defined by [CONTACT_675131] (R-IPSS) which evaluates cytogenetic risk, bone marrow blast count, 
hemoglobin, platelet count, and absolute neutrophil count, is associate d with 
median overall survival of 0.8 to 1.6 years and 0.7 to 1.4 years for  median time 
to 25% AML evolution. [ 4] Therapi[INVESTIGATOR_675110].   
Current approved therapi[INVESTIGATOR_675111]-risk MDS include cytotoxic 
chemotherapi[INVESTIGATOR_014], molecularly targeted therapi[INVESTIGATOR_14953] a fraction of eligible patients 
with FLT3/ ITD or IDH2 mutations, and immunotherapy in the form of allogeneic 
hematopoietic stem cell transplantation (HCT). There is a need for novel 
treatments that not only increase survival, but also can be well tolerated in this 
predominantly elderly population.    
 2.[ADDRESS_912429] been implicated in active AML a nd 
MDS. The tumor microenvironment is permissive towards preventing both innate 
and adaptive anti-leukemic immunity. Increased proportions of regulatory T-cells 
and myeloid-derived suppressor cells (MDSCs) have been identified in both AML 
and MDS patients as poor prognostic markers. [ 5][6][7] T-cells display aberrant 
gene expression activation patterns and form defective immune synapses in 
vitro.[ 8] Natural killer (NK) cell cytotoxicity is dampened by [CONTACT_675132].[ 9] Other pathways in AML and MDS 
that may contribute to immune dysfunction include PD-1/PD-L1, TIM3/Galectin -
9, and IDO-1.   
 2.3  PD-1/PD-L1 Pathway in Malignancies     
PD-1 is a member of the B7/CD28 family of 
co-stimulatory receptors that binds its 
ligands programmed death ligand-1 (PD-L1) 
and programmed death ligand-2 (PD-L2). 
PD-[ADDRESS_912430] highly expressed on 
activated mature T-cells, but also at low 
levels on NK cells, B-cells, and 
monocytes .[10] PD-1 binding of its ligand 
PD-L1 along with a co-stimulatory signal of 
T-cell receptor binding of the major 
histocompatibility complex (MHC) Figure 1. PD-
1/PD-L1 pathway  presenting an antigen results in reduced T-cell receptor 
signaling, activation, and cytotoxicity as a physiological termination of the 
immune response ( Figure 1 ). PD-1 overexpression is a phenotype of 
“exhausted,” dysfunctional T -cells in states such as chronic viral infection and 

HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 14 of 79   CPRC #2017LS116  malignancy. PD-L1 is constitutively expressed at a low level in professional 
and non-professional antigen presenting cells (APCs), but can be 
overexpressed in malignant cells as a mechanism of immune escape. To 
exploit this overactive immunosuppressive pathway, PD-1 blockade through 
nivolumab, a monoclonal antibody to PD-1, has been used to unleash tu mor-
directed cytotoxicity in multiple types of malignancy.   
The safety and efficacy of nivolumab has been established by [CONTACT_675133]. In melanoma, the randomized Checkmate-066 trial enrolled 
newly diagnosed metastatic melanoma patients to nivolumab or dacarbazine (n 
= 418) and reported higher ORR (34% vs. 9%) and median OS (not reached vs. 
10.8 months, HR 0.42, p<0.0001) in the nivolumab arm.[ 11] Responses were 
durable with 43 of 63 responding patients achieving ongoing response of 6  
months or longer. In patients with metastatic squamous non-small cell  lung 
cancer who had progressed on a platinum-containing regimen, nivolumab wa s 
compared to docetaxel (n = 272) in the Checkmate-017 trial and was asso ciated 
with significantly increased overall survival (median OS 9.2 months vs. 6 months, 
HR 0.59, p=0.0002).[ 12] In a similar study of metastatic non-squamous non-small 
cell lung cancer (n = 582) randomized to nivolumab or docetaxel, overall survival 
was 12.2 months for nivolumab vs. 9.2 months for docetaxel (HR 0.73, 
p=0.002).[ 13] Multiple other studies have solidified the role of PD-1 inhibitors in 
solid tumors including renal cell carcinoma, [ 14] squamous cell carcinoma of the 
head and neck, [ 15] and hepatocellular carcinoma. [ 16] Pooled safety analyses 
in melanoma trials (n=576) reported 71% (95% CI, 67% to 75%) with any-grade  
treatment-related adverse events (AEs) (most commonly fatigue [25%], pruritus 
[17%], diarrhea [13%], and rash [13%]), and 10% (95%CI, 8%to 13%) with grade 
3 to 4 treatment-related AEs. Median time to onset of AEs ranged from 5 weeks 
for skin to 15 weeks for renal AEs. [ 17]  
Within hematologic malignancies, PD-[ADDRESS_912431]-autologous transplantation enrolled 80 
patients and reported ORR of 66% (95% CI 54.8 –76.4) with acceptable safety 
profile. In the post-allogeneic transplantation setting of relapsed Hodgkin 
lymphoma, a multicenter retrospective review of 31 patients reported ORR of 
77%, with 55% rate of acute graft-versus-host disease (9 of 17 with grade II I-IV 
aGVHD or severe chronic GVHD) using standard 3 mg/kg nivolumab dosing. [ 18] 
A prospective phase I trial of nivolumab in relapsed hematologic malignancies 
reported dosing of 1 mg/kg (n = 6) and 0.5 mg/kg (n = 2). In the 1 mg/kg coh ort, 
1 patient had mild chronic GVHD and 2 patients had immune-related adverse 
events. [ 19]  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 15 of 79   CPRC #2017LS116  Nivolumab has been shown to be safe and well tolerated up to a dose level of 10 
mg/kg, and pharmacokinetic studies have not reported relationship between 
nivolumab exposure produced by 3 mg/kg and efficacy. This indicates that the 
safety and efficacy profile of 240 mg nivolumab is similar to that of 3 mg/kg 
nivolumab. Similarly, a flat dose of 360 mg corresponds to a dose o f 4.5 mg/kg 
q3w, which is similar to the nivolumab doses evaluated in combination with 
chemotherapy in [STUDY_ID_REMOVED], ranging from 5-10 mg/kg q3w. The simulate d 
steady state concentration at trough (Cminss), peak (Cmaxss), and average (Cavgss) 
with 360 mg are less than 10 mg/kg every 2 weeks. Thus, these regimens are  
expected to be safe and tolerable.   
 2.4  PD-1/PD-L1 Pathway in AML and MDS  
In AML, the PD-L1/PD-[ADDRESS_912432] is aberrantly upregulated in an estimate d 
4257% of AML patients,[ 20][21] with increased expression of PD-L1 on leukemic 
blasts at time of relapse [ 22] and increased expression of PD-[ADDRESS_912433] is 
associated with defective recognition and cytotoxicity towards leukemic blasts. 
[23]   
The immunosuppressive function of T-regs may be intimately connected t o 
aberrant PD-L1/PD-1 pathways. T-regs were unable to suppress CD8+ 
proliferation or cytokine secretion in both a PD-1 knockout AML mouse model 
and PD-1 wild-type AML mouse treated with monoclonal antibody to PD- L1. Treg 
depletion through IL2-diptheria toxin in combination with PD-1/PD-L1 blockade  
showed synergistic activity in reducing AML blast burden. [ 24] Murine models 
have demonstrated that PD-L1 overexpressing antigen-presenting cells may 
convert naïve T-cells into a T-regulatory phenotype and aid in their expansion  
and proliferation, although this has not been tested in an AML model.[ 25]  
Clinical trials of PD-1/PD-L1 blockade in AML are currently in early phase. 
CT011, a humanized IgG1 monoclonal PD-1 antibody, showed safety and 
tolerability in a phase 1 trial of advanced hematologic malignancies when given  
as a single dose of 0.2 to 6.0 mg/kg. [ 26] Seven of [ADDRESS_912434] reduction 
from 50% to 5% with two doses of CT-011 5 months apart, with disease control 
for 61 weeks.    
PD-L1 expression has also been widely detected in MDS, but may be more 
commonly expressed in non-leukemic immune cells than leukemic blasts (12% 
of CD34+ myeloid progenitor cells, 36% of CD34- myeloid progenitor cells, 26%  
of lymphocytes).[ 27] Another study showed increased PD-1 expression in two 
subtypes of T-regs as well as CD4+ effector memory T-cells in MDS patients 
compared to healthy controls.[ 28] PD-L1 expression may increase after failure of 
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 16 of 79   CPRC #2017LS116  hypomethylating agents (HMA), suggesting PD-L1 upregulation as a mechan ism 
of resistance to HMAs.   
Nivolumab has been studied as monotherapy and in combination with 
azacitadine in a phase II study of MDS patients after failure of hypomethylatin g 
agents. Although efficacy was seen with objective response rate of 69% in th e 
combination arm (n = 13), there was no single agent activity noted in the 
Nivolumab monotherapy arm (n = 15). Pembrolizumab monotherapy was stud ied 
in 28 patients with MDS after HMA failure in the phase 1b KEYNOTE-013 stu dy, 
which showed ORR of 4%, stable disease in 52%, and hematologic improvement 
in 11%. [29]  
 2.5  Low Dose Cyclophosphamide  
Cyclophosphamide (CTX) is an alkylating agent with differential effects at high 
and low doses. At maximal tolerated dose, it exerts broad anti-proliferative, 
cytotoxic effects in a variety of malignancies. At low, continuous dosing 
(“metronomic”), it has immunomodulatory and anti -angiogenic properties as a 
monotherapy or in combination with other agents.   
Low dose CTX has been reported to decrease number of FOXP3+ regulato ry 
Tcells, although this effect has not been sustained in most studies. [ 41] In vitro 
studies have additionally shown an attenuation of T-reg function and proliferative  
abilities.[ 42] Other immunomodulating effects of low dose CTX include 
polarization of CD4+ helper T-cells towards a Th1 profile that secrete type-1 IFNs 
and IL-2, favorable for conversion into a memory CD8+ T-cell phenotype,[ 43] and 
increased Th17+ population that secrete the pro-inflammatory cytokine IL-17.[ 44] 
In heavily pre-treated metastatic breast cancer patients, daily oral CTX at [ADDRESS_912435] shown 
sustained increase in proliferative capacity of CD8+ effector T-cells. [ 45] Most 
studies of low dose CTX are in breast cancer, but efficacy has also been sh own 
in hormone-resistant prostate cancer [ 46] and metastatic melanoma [ 47].   
The immunomodulatory properties of cyclophosphamide have been exploited by 
[CONTACT_675134]. Preconditioning with low dose CTX in murine models of colon cancer 
and melanoma resulted in enhanced numbers of antigen-specific T-cells an d 
increased tumor regression.[ 48] In addition to enhancing effector T-cells, CTX 
has been shown to increase number and activation status of dendritic cells in a 
murine model of colon cancer. [ 49] A combination of dendritic cell vaccine, low 
dose CTX, and anti- PD-1 therapy was effective in inducing an antigen-specific 
immune response leading to long-term tumor control in a murine model of glioma. 
[50]  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 17 of 79   CPRC #2017LS116  Within hematologic malignancies, the use of continuous low dose CTX has b een 
limited to non-Hodgkin lymphoma and multiple myeloma in combination with 
other agents. CTX and high-dose Celecoxib in a phase II trial had efficacy in a 
population of relapsed and refractory non-Hodgkin lymphoma patients, with 37% 
ORR and median PFS of 4.7 months.[ 51] To date, there are no published studies 
of low dose CTX for treatment of MDS or AML.    
Low dose CTX also has known anti-angiogenic effects, promoting normalization 
of the bone marrow vasculature through upregulation of thrombospondin- 1 
(TSP1), a glycoprotein with potent endogenous angiogenesis inhibiting 
properties. [ 52] [53] Endothelial cells have been reported to be very sensitive to 
low doses of CTX. Induction of hypoxia results in disruption of endothelial cell  
ability to form tubes and leads to apoptosis.[ 54] In-vitro studies suggest a 
synergistic mechanism of CTX with other anti-angiogenic agents. Anti-
angiogenic effects of CTX have been mainly studied in solid tumor models. I n 
AML, the role of angiogenesis in the vascular niche of leukemic blasts and stem 
cells has been investigated. Significantly increased microvascular density has 
been observed in the bone marrow of AML patients compared to he althy 
controls,[ 55] and may be a poor prognostic feature.[ 56] Induction of TSP-1 can 
directly induce apoptosis in AML cell lines, and is a potential therapeutic 
mechanism of low dose CTX in this setting. [ 57] While not proposed for direct 
testing, this may be a contributing therapeutic effect of the proposed therapy.   
 2.6  IL-15  
Interleukin-15 (IL-15) is a cytokine and growth factor capable of expand ing 
activated T cells and NK cells. By [CONTACT_625246], the NCI Immunotherapy 
Workshop (2007) ranked IL- 15 as the #1 agent with “high potential for 
immunotherapy.”[ 58] Based on preclinical non-human primate and early phase 
clinical trial data, including those at the University of Minnesota, IL- 15-containing 
regimens can be designed to prospectively and reproducibly increase T-cell and 
NK-cell counts.  
  
The NCI Biological Resource Branch has manufactured E. coli-expressed 
recombinant human IL-15 (rhIL-15); daily administration of rhIL-15 intraveno usly 
(IV) or subcutaneously (SC) has been shown to increase the number and 
activation status of circulating CD8+ T and NK cells, but the cytokine has a very 
short half-life. Furthermore, high levels of free rhIL-15 decrease circulating IL- 
15Rα, acting as a negative feedback signal to reduce further IL -15 
transpresentation. Trans-presentation appears to be a dominant mechanism for 
IL- 15 action in vivo in response to immune stimuli.[ 59] N-803 (Nantcell Inc, 
Culver City, CA) is a soluble complex consisting of two protein subunits of a 
human IL-15 variant associated with high affinity to a dimeric human IL- 15 
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 18 of 79   CPRC #2017LS116  receptor α (IL - 15Rα) sushi domain/h uman IgG1 Fc fusion protein, that 
physiologically transpresents IL-15.[ 60][61] The IL-15 variant is a 114 aa 
polypeptide comprising the mature human IL-15 cytokine sequence with an  Asn 
to Asp substitution at position 72 of helix C (N72D)12. The human IL- 15Rα sushi 
domain/human IgG1 Fc fusion protein comprises the sushi domain of the hu man 
IL-15 receptor α subunit (IL -15Rα) (aa 1 -65 of the mature human IL- 15Rα 
protein) linked with the human IgG1 CH2-CH3 region containing the Fc doma in 
(232 amino acids). Aside from the N72D substitution, all of the protein sequ ences 
are human. N-803 has a prolonged serum half-life in preclinical animal mode ls 
and has a 4-fold increase in biologic activity greater than wild-type IL-15 (IL- 15 
wt). [ 60]  
N-[ADDRESS_912436] good tolerability and some clinical activity. [ 62] N-803 in 
combination with Nivolumab was safe and had clinical activity in a study of 
advanced non-small cell lung cancer patients with previous progression on single 
agent PD-1 inhibitor.[ 63] A summary of N-803 by [CONTACT_675135] 6.1.4 . The University of Minnesota’s experience with N -[ADDRESS_912437] notable event, often quite widespread; however no ne were 
dose limiting. Typi[INVESTIGATOR_897], the rash resolved by [ADDRESS_912438] 
on day 4, and decreased with subsequent doses. [ 62] [63] This suggests that 
prolonged continuous treatment leads to immune anergy and reduced biological 
responsive. Thus subsequent studies using this agent have been amended to 
use less frequent dosing schedules for N-803 ([STUDY_ID_REMOVED]). This study will 
use every 3 week dosing at 10 ug/kg given subcutaneously.    
 2.7  Areas of Investigation    
The somatic mutational profile of AML (Cancer Genome Atlas Project) may be 
simpler than most solid tumors, with an average of only 13 mutations pe r gene, 
though it may be two-fold greater in secondary AML. [64] Cancers with high 
somatic mutation frequency have shown variable sensitivity to single agent PD1 
blockade, from 50-60% clinical benefit with durable response in melanoma to low 
efficacy in squamous cell carcinoma of the lung, suggesting that other factors 
contribute to predicting response to checkpoint blockade. Within AML, Wilms 
Tumor (WT) has been identified as a potential neo-antigen targetable with a 
WTspecific cytotoxic T-cell response. Subgroups of AML with mutations 
including FLT3/ ITD or NPM1 may also have neo-antigen targets and might 
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 19 of 79   CPRC #2017LS116  benefit from PD-[ADDRESS_912439]. [ 39]  
The function and activity of dendritic cells to either induce antigen-directed 
cytotoxicity or anergy in T-cells in AML and MDS is an important variable in 
efficacy of PD-1/PD-L1 directed therapy. Dendritic cells have been classified into 
two groups, myeloid and plasmacytoid, based on expression of CD11c, both 
which can be derived from a malignant clone.[ 65] AML-derived DCs, particularly 
the plasmacytoid variant, have been reported to express tolerogenic cytokines 
such as IL-10 and secrete IDO, which induces an immunosuppressive 
Tregulatory response.[ 66] A study of MDS patients reported reduced numbers of 
peripheral blood DCs that were all clonally-derived. [67] In newly diagnosed AML 
patients, a small study showed a range of normal quantitative DC subsets, 
increased DC subsets, or no detectable DC subsets. Functional studies showed 
reduced ability to induce proliferative responses in naïve T-cells in DCs from AML 
patients compared to healthy controls. [ 68] Further understanding of the role of 
DCs in tumor evasion in the setting of relapsed/refractory AML and MDS may 
enhance delivery of effective immunotherapi[INVESTIGATOR_014].   
 2.[ADDRESS_912440] to eliminate leukemic blasts and 
leukemiainitiating cells/leukemia stem cells highlights its curative potential. Many 
patients are not eligible for alloHCT due to pre-existing comorbidities, lack of 
donor graft availability, older age, and excessive leukemia burden. Immune 
checkpoint inhibitors of the PD-1/PD-L1 pathway have widespread efficacy 
across multiple cancer types and favorable tolerability. This research 
hypothesizes that PD-1 inhibitors in combination with immunomodulatory ag ents 
will induce leukemiadirected immune stimulation in AML and higher-risk MDS. 
Low dose cyclophosphamide is an immunomodulator which has not been 
reported to cause severe myelosuppression in a population that commonly has 
neutropenia and increased risk of infection due to active disease. N-803 is a 
promising immunotherapeutic agent that is safe, has known synergistic activity 
with PD-1 inhibitors, and is highly potent for increasing frequency and activation 
of T-cells and NK cells. Immune dysfunction induced by [CONTACT_675136]2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 20 of 79   CPRC #2017LS116  from additional stimulation with an agent such as N-803 to induce T-cell  
cytotoxicity after PD-1 blockade.   
3 Study Design   
This phase I study consists of a randomized pi[INVESTIGATOR_14733]-study of two dosage arms  of CTX 
in combination with nivolumab and N-803 in stage I.    
  
Arm 1 (CTX 50 mg PO daily + nivolumab IV) and Arm 2 (CTX 350 mg PO e very 7 days+ 
nivolumab IV) previously enrolled randomized patients in a 1:1 ratio. Due to low 
response rates (no complete responses and only 2 patients with partial response ) and 
4 patients receiving ≤[ADDRESS_912441] 20 patients enrolled in the study 
are randomized to either Arm 3 (CTX 50 mg PO daily + nivolumab IV + SC N -803 every 
3 weeks) or Arm 4 (CTX 350 mg PO every 7 days+ nivolumab IV + SC N-803 every 3 
weeks) with 10 subjects in each arm. Nivolumab is dosed at 360 mg, unless the p atient 
has had a prior allogeneic hematopoietic stem cell transplant (alloHSCT), in which case 
nivolumab is given at 180 mg IV every 3 weeks. N-803 is dosed at 10 ug/kg every [ADDRESS_912442] disease, and any Grade 4 or 5 non-hematologic event, will be used t o 
monitor excessive toxicity for each arm.   
  
Efficacy will be assessed with pooled total from both arms 3 and 4 with up  to 20 patients 
available for assessment of OR at 42 days.   
  
All patients receive nivolumab IV over 30 minutes every 3 weeks, N-803 SC eve ry 3 
weeks and oral cyclophosphamide as assigned for up to 5 treatment courses with each 
treatment course equal to 21 days. Nivolumab is dosed at 360 mg, unless th e patient 
has had a prior allogeneic hematopoietic stem cell transplant (alloHSCT), in which case 
nivolumab is given at 180 mg IV every 3 weeks.  N-803 is dosed at 10 ug/kg every [ADDRESS_912443] count is <25% in peripheral blood or bone 
marrow  from baseline at day [ADDRESS_912444] dose of study drug with follo w-up for 
response and survival continuing through 2 years from beginning of treatmen t. For 
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 21 of 79   CPRC #2017LS116  patients with clinical benefit after the 5 treatment courses, additional therapy wi th the 
study drugs or other treatment may be offered.  
4 Patient Selection  
Study entry is open to patients 18 years of age and older regardless of ge nder, race, or 
ethnic background. While there will be every effort to seek out and include min ority 
patients, the patient population is expected to be no different than that of other 
relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic 
syndrome studies at the University of Minnesota.  
4.1 Inclusion Criteria  
4.1.1  ≥18 years of age   
4.1.2  Meets one of the following disease criteria:  
• Primary (de novo) AML or higher-risk MDS with induction failure: No 
CR after 2 or more induction attempts with chemotherapy, 
hypomethylating, agents or other agents; no CR after 1 induction 
attempt and not eligible for a 2nd induction. Higher risk MDS defined 
as risk score > 4.5 based on the revised IPSS criteria (refer to  
Appendix  
II).     
• Secondary AML (from antecedent hematologic malignancy or 
treatment-related): Not in CR after 1 or more cycles of chemotherapy.   
• Relapsed AML: Blasts ≥5% in bone marrow  or peripheral blood after 
prior attainment of CR or biopsy-proven extramedullary leukemia in 
absence of bone marrow involvement; relapse at any time but 
currently ≥[ADDRESS_912445].  
• Relapsed MDS: Morphologic evidence of relapse or increase in blasts 
to ≥5% in bone marrow or peripheral blood after prior hematolog ic 
improvement or partial or complete response and not eligible for or 
decline intensive chemotherapy; relapse at any time but currently 
≥[ADDRESS_912446].   
4.1.3  ECOG Performance Status ≤ 2 –  refer to Appendix I   
4.1.4  Adequate organ function within 14 days of study registration defined as:  
• Absolute Lymphocyte Count:   ≥ 500 cells/mm3  
• Hepatic:   total bilirubin ≤ 3 x upper limit of institutional normal (ULN); 
ALT and AST ≤ [ADDRESS_912447]  
• Renal: Serum creatinine ≤ 2 mg/dL   
• Pulmonary: No oxygen requirement on room air or requiring ≤ 2L 
supplemental O 2  
4.1.5 Ability to be off prednisone and other immunosuppressive drugs (>10 mg 
daily prednisone equivalent) for at least 14 days prior to and while receiving 
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 22 of 79   CPRC #2017LS116  N-803. Inhaled or topi[INVESTIGATOR_8826], and adrenal replacement steroid doses 
< [ADDRESS_912448] agree to use effective contraception duri ng 
therapy and continuing (23 weeks for females, 31 weeks for males) after 
the last dose of nivolumab  
4.1.7  Voluntary written consent   
4.2 Exclusion Criteria  
4.2.1  Pregnant or breastfeeding –The agents used in this study fall under 
Pregnancy Category D - Drugs which have caused, are suspected to have 
caused or may be expected to cause, an increased incidence of human 
fetal malformations or irreversible damage. Women of childbearing 
potential must have a negative pregnancy test (urine or serum) within 7 
days of study drug administration.  
4.2.2  Prior allogeneic hematopoietic stem cell transplantation currently within  
previous 100 days (note patients with a prior alloHSCT receive nivolumab 
at the reduced dose of 180 mg); they are eligible after that date  
4.2.[ADDRESS_912449] disease   
4.2.4 Active pneumonitis or uncontrolled infection  
4.2.5 Received chemotherapy drugs within previous 2 weeks  
4.2.6  Estimated life expectancy <28 days in the opi[INVESTIGATOR_417858]  
4.2.7 Previously treated with N- 803 (or “ALT -803”)  
4.2.[ADDRESS_912450] be obtained prior to the performance of an y research 
related tests or procedures. Consent is usually obtained before final eligibility is 
determined.  
5.1 Consent and Study Screening in OnCore  
Any patient who has been consented is to be entered in OnCore by [CONTACT_675137] (PCRC) or designee. If a patient is consented, but 
not enrolled, the patient’s record is updated in OnCore as a screen failure and 
reason for exclusion recorded.  
5.[ADDRESS_912451] sign the treatment consent 
and meet each of the inclusion criteria and none of the exclusion on the e ligibility 
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 23 of 79   CPRC #2017LS116  checklist based on the eligibility assessment documented in the patient’s med ical 
record.  
  
The Primary Clinical Research Coordinator (PCRC) or designee will complete 
the enrollment process in OnCore by [CONTACT_675138] g 
the on treatment date.  
  
Up to 20 patients enrolled in the study are randomized via OnCore at the time of  
study registration to either:   
Arm 3: CTX 50 mg PO daily + nivolumab 360 mg (or if prior alloHSCT, 18 0 mg) 
IV every 3 weeks + SC N-803 10 ug/kg every 3 weeks or   
Arm 4: CTX 350 mg PO every 7 days + nivolumab 360 mg (or if prior alloHSCT, 
180 mg) IV every 3 weeks + SC N-803 10 ug/kg every 3 weeks  
  
No additional patients will be enrolled to Arm 1 or 2 (closed). If Arm [ADDRESS_912452] 
dose of study drug, for whatever reason, the patient will be removed from study 
and treated at the physician’s discretion. The study staff will update OnCore  of 
the patient’s non -treatment status (off study). The reason for removal from study 
prior to starting study treatment will be clearly indicated in OnCore. The patient 
will be replaced to fulfill study enrollment requirements.  
6  Treatment Plan  
In order to provide optimal patient care and to account for individual medical conditions , 
investigator discretion may be used in the prescribing of all supportive care dru g therapy 
(i.e. acetaminophen, diphenhydramine, antimicrobials, etc.).   
6.1 Study Drug Administration  
Participants will receive one of the two following treatment plans based on 
assignment at enrollment:  
  
Arm 3: CTX 50 mg PO daily + nivolumab 360 mg (or if prior alloHSCT, 18 0 mg) 
IV every 3 weeks + SC N-803 10 ug/kg every 3 weeks or   
Arm 4: CTX 350 mg PO every 7 days + nivolumab 360 mg (or if prior alloHSCT,  
180 mg) IV every 3 weeks + SC N-803 10 ug/kg every 3 weeks  
  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 24 of 79   CPRC #2017LS116  Each treatment course consists of 3 weeks with up to 5 treatment courses 
permitted. A window of ±3 days is permitted for the nivolumab infusion to 
accommodate scheduling difficulties (i.e. holidays, inclement weather).   
  
To begin a new treatment course (Day 1) the following criteria must be met:  
• Cyclophosphamide  
o No grade 3-4 oral mucositis or grade 3- 4 
cystitis   o No signs or symptoms of new 
infection   
• Nivolumab o No contraindication for continuation based on immune-
related adverse events (see Section 7.1 )  
o No signs or symptoms of new infection   o No 
active GVHD  
• N-803  o Previous injection site reaction is not showing signs of resolving  
(improving) based on measurement or intensity  o No 
hypotension (systolic blood pressure <90 mmHg) not resolving with 
intravenous fluids   
o No contraindication for continuation based on 
immune-related adverse events (see Section 
7.1)  
o No signs or symptoms of new infection  o No 
active GVHD   
  
Patients who have delay of nivolumab and/or N-[ADDRESS_912453] study treatment discontinued, unless the treating physicia n 
considers that the patient may benefit from continued study treatment after 
resolution of AEs.   
If nivolumab is delayed, N-803 and/or cyclophosphamide should continue if n o 
contraindication is present.   
If N-803 is delayed, nivolumab and/or cyclophosphamide should continue if no 
contraindication present.   
If cyclophosphamide is delayed, nivolumab and/or N-803 should continue if n o 
contraindication present.   
If nivolumab and N-803 are both permanently discontinued, cyclophosphamide  
should be discontinued and patient should be taken off study.   
6.1.1  Nivolumab (All Participants)  
Nivolumab will be given at a fixed dose of 360 mg (or if prior alloHSCT, 180 mg) 
IV over 30 minutes every 21 days on Days 1 of each cycle for up to five 21-day  
courses.    
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 25 of 79   CPRC #2017LS116    
Nivolumab will be administered in the outpatient setting; however, inpatient 
administration is permitted as medically appropriate if a patient is hospi[INVESTIGATOR_057].  
No premedication is required. Monitoring will be according to institutional 
guidelines with interruption or slowing of rate of infusion with grade 1 to 2 
infusional toxicities and discontinuation of nivolumab with grade 3 to 4 infusional 
toxicities.   
  
No dose modifications are permitted for nivolumab but dose may be withheld 
based on occurrence of significant immune-related AE Grade 2 or higher base d 
on NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.03, as 
described in Section 7.1 .  
6.1.2 Oral Cyclophosphamide (CTX) Administered Daily (Arm 3)  
The patient should be instructed to take CTX once a day, every day, by [CONTACT_675139]. The tablet must be swallowed whole, 
with a full glassful of water. Cyclophosphamide tablets are best taken early in the  
day about an hour before a meal. However, to avoid queasiness, it may be take n 
with food. The patient should be encouraged to drink plenty of liquids.  
  
If a dose is missed and it is more than [ADDRESS_912454] skip the missed dose, 
recording the dose as missed on the daily drug log.  
6.1.3 Oral Cyclophosphamide (CTX) Administered Weekly (Arm 4)  
The patient should be instructed to take CTX once weekly at approximately the 
same time each week. The tablet must be swallowed whole, with a full glassful  
of water. Cyclophosphamide tablets are best taken early in the day a bout an hour 
before a meal. However, to avoid queasiness, it may be taken with fo od. The 
patient should be encouraged to drink plenty of liquids.  
  
If a dose is missed, it may be taken if less than [ADDRESS_912455] skip the missed dose  
and resume at next scheduled dose if clinically appropriate.   
6.1.4 N-803 (All Participants)  
N-803 at 10 ug/kg is administered subcutaneously on D1 of a 21-day cycle fo r a 
maximum of 5 doses, or until stoppi[INVESTIGATOR_675112]. A windo w 
of +/- 1 week if permitted for each N-803 injection in the event of sched uling 
issues (i.e. holiday, bad weather, or other scheduling issues). N-803 will b e 
administered in the outpatient setting; however, inpatient administration is 
permitted as medically appropriate if a patient is hospi[INVESTIGATOR_057].  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 26 of 79   CPRC #2017LS116    
N-[ADDRESS_912456] 
dose. For patients > 100 kilograms weight, the N-803 dose is calculated using a 
weight capped at 100 kg. The patient’s wei ght is re-checked prior to each dose 
(within 7 days) and the dose re- calculated if ≥ 10% change from the weight used 
for the previous dose calculation. Rounding of a dose is permitted per inst itutional 
policy.   
  
If the total subcutaneous dose is greater than 1.[ADDRESS_912457] dose of N -803 
for immediate adverse events. Vital signs (heart rate, blood pressure, respi[INVESTIGATOR_1516], 
temperature, and oxygen saturation) will be documented prior to the N -803 
injection and then at 30, 60 and 120 minutes with a ± [ADDRESS_912458] dosing observation period. Vital signs (heart rate, blood 
pressure, respi[INVESTIGATOR_1516], temperature, and oxygen saturation) will be documented 
prior to each N-803 injection and then at 30 minutes ± 10 minutes.  
6.1.5 Dose Reduction  
A one-time dose decrease to 6 mcg/kg is allowed for recurrent N-803 related 
constitutional symptoms (e.g. fever, fatigue, muscle aches) interfering with 
activities of daily living (ADL) despi[INVESTIGATOR_95922]-medication. Patients unable to tolerate 
the reduced dose will be discontinued from further N-803. Re-escalation of th e 
dose is not permitted.  
6.[ADDRESS_912459]   
New or worsening skin rash outside of injection site area and other GVHD 
manifestations should be managed per institutional guidelines. Refer to Section 
7.3 for management of skin rash/injection site reaction within the vicinity of the 
injection.  
  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 27 of 79   CPRC #2017LS116  GVHD will be graded using the University of Minnesota aGVHD Grading Scale 
(Appendix IV ).   
  
N-[ADDRESS_912460] count leukemia for 
up to 1 month after enrollment in study.    
  
Steroids or other immune modulatory medications should be avoided un less 
required for treating a grade 3-4 Nivolumab or N- 803-related adverse event.    
  
Supportive Care will be provided per University of Minnesota institutional 
guidelines.   
 6.4  Duration of Study Treatment  
Patients will receive five 21-day treatment courses unless any one of the 
following occurs:  
• Unacceptable toxicity  
• Progression as defined by [CONTACT_675140] ≥25% in 
peripheral blood or bone marrow by [CONTACT_4475] 42 or later   
• A different anti-cancer treatment is indicated  
• Patient is non-compliant or refuses treatment  
• In the opi[INVESTIGATOR_80021], continuation of study therapy is 
not of benefit to the patient   
  
A final treatment visit occurs [ADDRESS_912461] dose of study drug (ma ximum 
of 5 courses).    
  
Any patient unable to receive at least [ADDRESS_912462] with a local medical doctor 
unless the patient is:  
• Unevaluable (e.g. unable to receive at least 1 cycle of study therapy)  
• enters hospi[INVESTIGATOR_3677]  
• refuses follow- up  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 28 of 79   CPRC #2017LS116    
After [ADDRESS_912463] review will continue until  2 
years from study enrollment.   
  
The date and cause of death should be entered into the follow-up  tab in OnCore 
upon knowledge.  
 7  Management of Selected Toxicity   
The NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 will 
be used to grade adverse events. A copy of the CTCAE v 4.03 can be downloaded: 
(https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-
0614_QuickReference_8.5x11.pdf).  
7.1 Nivolumab and N- 803  
Immune-Related Adverse Events Management   
Immune-related adverse events (irAEs) from nivolumab and N-803 will be 
managed depending on severity (NCI CTCAE 4.03 grade) as outlined below.   
Grade 1 to 2: Treat symptomatically or with moderate dose steroids, more 
frequent monitoring.  
Grade 1 to 2 (persistent): Manage similar to Grade 3 to 4 irAE  
Grade 3 to 4:  Treat with high dose corticosteroids  
Any Grade [ADDRESS_912464] a ny 
clinical correlate, and resolve within 7 days with adequate medical management  
Any Grade 3 irAEs require withholding nivolumab and N-803 except for any 
of the following:  Transient (≤ 6 hours) Grade 3 flu -like symptoms or fever, which 
is controlled with medical management, transient (≤ 24 hours) Grade 3 fatigue, 
local reactions, headache, nausea, em esis that resolves to Grade ≤ 1 and  single 
laboratory values out of normal range (excluding Grade ≥ [ADDRESS_912465] 
increase) that are unlikely related to study treatment according to the 
Investigator, do not have any clinical correlate, and resolve to Grade ≤ 1 within 7 
days with adequate medical management   
Any Grade 2 irAEs should be managed as follows:  
If a Grade 2 irAE resolves to Grade ≤ 1 by [CONTACT_319553], treatment may 
continue.  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 29 of 79   CPRC #2017LS116  If a Grade 2 irAE does not resolve to Grade ≤ 1 by [CONTACT_675141], 
treatment should be withheld at next cycle. If at the end of the fo llowing cycle the 
event has not resolved to < Grade 1, the subject should permanently discontinue  
treatment with nivolumab and N-803 (except for hormone insufficiencies , that can 
be managed by [CONTACT_13128]).   
  
Upon the recurrence of the same Grade 2 irAE (except for hormone 
insufficiencies that can be managed by [CONTACT_13128]) in the same 
subject, treatment with nivolumab and N-803 should be permanently 
discontinued. Treatment of gastrointestinal, dermatological, pulmonary, hepatic, 
renal, cardiac, neurological and endocrine irAEs should follow guidelines set forth 
in the table below.  
Gastrointestinal irAEs  
Severity of  
Diarrhea/Colitis  Management   Follow- up  
Grade 1  
Diarrhea: < 4 
stools/day over 
baseline  
Colitis: asymptomatic   Continue nivolumab and N-
803 therapy  
Symptomatic treatment (for 
example, loperamide)  Close monitoring for worsening  
symptoms  
Educate subject to 
report worsening 
immediately If worsens:  
Treat as Grade 2 or 3/4   
Grade 2  
Diarrhea:  4 to 6 
stools per day over 
baseline; IV fluids 
indicated < 24 hours;  
not interfering with  
ADL  
Colitis:  abdominal 
pain; blood in stool   Withhold nivolumab and N- 
803   
Symptomatic treatment  If improves to Grade <1:   
Resume nivolumab and N- 803 
therapy  
If persists > 5-7 days or recur  
• 0.5-1.0 mg/kg/day 
methylprednisolone or oral 
equivalent  
• When symptoms improve to  
grade 1, taper steroids at least 1 
month, consider prophylactic 
antibiotics for opportunistic 
infections, and resume I- O  
therapy per protocol  
  
If worsens or persists > 3-5 with 
oral steroids, then treat as Grade  
3 to 4  
  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 30 of 79   CPRC #2017LS116  Grade 3 to 4  
Diarrhea (Grade 3): ≥  
7 stools per day over  
Baseline; 
incontinence; IV fluids 
≥ 24 hrs.; interfering 
with ADL  
Colitis (Grade 3):  
severe abdominal 
pain, medical 
intervention indicated, 
peritoneal signs 
Grade 4: 
lifethreatening, 
perforation  Permanently discontinue 
nivolumab and N-803 for  
Grade 4   
  
Withhold nivolumab and 
N803 for Grade 3   
  
1.0 to 2.0 mg/kg/day 
methylprednisolone IV or  
equivalent Add 
prophylactic  
antibiotics for opportunistic 
infections   
Consider colonoscopy if  
needed   If improves, continue steroids 
until Grade < 1, then taper over at 
least 1 month  
If worsens, persists > 3 to 5 days, 
or recurs after improvement, add 
infliximab 5 mg/kg (if no 
contraindication), Note: Infliximab 
should not be used in cases of  
perforation or sepsis   
  
Grade 3:  If improves to Grade  
≤1: Resume nivolumab and N803 
therapy  
  
    
 
Dermatological irAEs  
Grade of Rash  Management  Follow- up  
Grade 1 to 2  
Covering ≤ 30% body 
surface area  Symptomatic therapy (for 
example, antihistamines, 
topi[INVESTIGATOR_8826])  
Hold nivolumab and N803, 
may resume if resolving 
after 1 week   If persists > 1 to 2 weeks or 
recurs:  
Consider skin biopsy  
Delay nivolumab and N-803. 
Consider 0.5 to 1.0 mg/kg/day 
methylprednisolone IV or oral 
equivalent. Once improving, taper 
steroids over at least 1 month, 
consider prophylactic antibiotics 
for opportunistic infections, and 
resume nivolumab. If worsens. 
treat as Grade 3 or 4  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 31 of 79   CPRC #2017LS116  Grade 3 to 4  
Covering > 30%  
Grade 4: body surface 
area; life threatening 
consequences   Withhold nivolumab and N- 
803 for Grade 3  
Permanently discontinue 
nivolumab and N-803 for  
Grade 4 or recurrent  
Grade 3  
Consider skin biopsy,  
Dermatology consult  1.0 
to 2.0 mg/kg/day 
methylprednisolone IV or  
IV equivalent   If improves to <Grade 1, taper 
steroids over at least [ADDRESS_912466] every 3 weeks  
If worsens, treat as Grade 2 or 34   
 
Grade 2  
Mild to moderate new 
symptoms   Delay nivolumab and N- 
803 therapy  
Pulmonary and Infectious  
Disease consults 
Monitor symptoms daily, 
consider hospi[INVESTIGATOR_059]  
1.0 mg/kg/day 
methylprednisolone IV or 
oral equivalent   
Consider bronchoscopy, 
lung biopsy   Re-image every 1-3 days  
When symptoms improve to  
Grade < 1, taper steroids over at 
least 1 month and then resume 
nivolumab and consider 
prophylactic antibiotics  
If not improving after 2 weeks or 
worsening, treat as Grade 3 to 4   
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 32 of 79   CPRC #2017LS116  Grade 3 to 4 
Severe new 
symptoms; New / 
worsening hypoxia; 
life-threatening   Permanently discontinue 
nivolumab and N-803  
Hospi[INVESTIGATOR_675113] 
2 to 4 mg/kg/day  
methylprednisolone IV or  
IV equivalent  
Add prophylactic  
antibiotics for opportunistic 
infections   
Consider bronchoscopy, 
lung biopsy   When symptoms improve to  
Grade < 1, taper steroids over at 
least 6 weeks  
If not improving after 48 hours or 
worsening:, add additional 
immunosuppression (for example, 
infliximab, cyclophosphamide, IV 
immunoglobulin, or  
mycophenolate mofetil)   
  
Hepatic irAEs  
Grade of Liver Test 
Elevation  Management  Follow- up  
Grade [ADDRESS_912467] or ALT 
> ULN to 3.[ADDRESS_912468]  
and / or total bilirubin  
> ULN to 1.[ADDRESS_912469] or ALT > 3.0 to ≤ 
[ADDRESS_912470] and / or total  
bilirubin > 1.5 to ≤ [ADDRESS_912471]   Withhold nivolumab and  
N-803  
Increase frequency of 
monitoring to every 3 
days   If returns Grade < 1,  resume 
routine monitoring, resume 
nivolumab and N-[ADDRESS_912472] > 5-7 days or 
worsens, 0.5 to 1 mg/kg/day 
methylprednisolone or oral  
equivalent and when LFT returns to 
Grade < 1, taper steroids over at 
least 1 month, consider prophylactic 
antibiotics for  
  opportunistic infections, resume 
nivolumab and N-803  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 33 of 79   CPRC #2017LS116  Grade [ADDRESS_912473] or ALT > [ADDRESS_912474] 
and / or total bilirubin 
> [ADDRESS_912475]   Permanently discontinue 
nivolumab and N-803 
Increase frequency of 
monitoring to every 1 to  
2 days   
1.0 to 2.0 mg/kg/day 
methylprednisolone IV or  
IV equivalent Add 
prophylactic 
antibiotics for  
opportunistic infections, 
Consult 
gastroenterologist 
Consider obtaining  
MRI/CT scan of liver and 
liver biopsy if clinically  
warranted   If returns to Grade < 1, taper 
steroids over at least 1 month  If 
does not improve in >3 - 5 days, 
worsens or rebounds, add 
mycophenolate mofetil 1 gram (g) 
twice daily   
If no response within an additional  
3 to 5 days, consider other 
immunosuppressants per local 
guidelines   
   
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 34 of 79   CPRC #2017LS116  Renal irAEs  
Grade of Creatinine 
Elevation  Management  Follow- up  
Grade 1  
Creatinine > ULN and  
> than baseline but ≤  
1.5x baseline  Continue nivolumab and  
N-803  
Monitor creatinine weekly  If returns to baseline:  
•Resume routine creatinine 
monitoring per protocol If 
worsens:  
•Treat as Grade 2 or 3/4  
Grade 2- 3 
Creatinine > 
1.5x baseline to 
≤ 6x ULN  Delay nivolumab and N- 
803  
Monitor creatinine every  
2-3 days  
0.5 to 1.0 mg/kg/day 
methylprednisolone IV or 
oral equivalent Consider 
renal biopsy with 
nephrology consult  If returns to Grade 1:  
•Taper steroids over at least [ADDRESS_912476] > 7 days or 
worsen:  
•Treat as Grade 4  
Grade 4  
Creatinine > 6x ULN  Permanently discontinue 
nivolumab and N-803  
Monitor creatinine daily  
  
1.0-2.0 mg/kg/day 
methylprednisolone IV or 
IV equivalent  
Consult nephrologist  
Consider renal biopsy  If returns to Grade 1 : Taper 
steroids over at least 1 month and 
add prophylactic antibiotics for 
opportunistic infections  
    
Neurological irAEs  
Grade of  
Neurological 
Toxicity  Management  Follow- up  
Grade 1  
Asymptomatic or 
mild symptoms; 
Intervention not 
indicated  Continue nivolumab and 
N-803  If returns to baseline:  
•Resume routine monitoring per 
protocol If worsens:  
•Treat as Grade 2 or 3/4  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 35 of 79   CPRC #2017LS116  Grade 2  
Moderate symptoms; 
Limiting instrumental  
ADL  Delay nivolumab and N- 
803  
Treat symptoms per local 
guidelines Consider 0.5 
to 1.0 mg/kg/day  
methylprednisolone IV or  
PO equivalent  If returns to baseline:  
• resume  nivolumab and N-803 
therapy when returned to baseline 
If worsen:  
•Treat as Grade 3 -4  
Grade 3- 4  
Severe symptoms;  
Limiting self-care  
ADL;  
Life-threatening  Permanently discontinue 
nivolumab and N-803 
Obtain neurology consult 
Treat symptoms per local 
guidelines  
1.0-2.0 mg/kg/day IV 
methylprednisolone IV or  
IV equivalent Add 
prophylactic antibiotics 
for opportunistic 
infections  If improves to Grade 2:  
Taper steroids over at least 1  
month  
If worsens or atypi[INVESTIGATOR_31790]: 
Consider IVIG or other 
immunosuppressive therapi[INVESTIGATOR_675114]- up  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 36 of 79   CPRC #2017LS116  Grade 2  
Symptoms with mild  
to  
moderate activity or 
exertion  
  Withhold nivolumab and N- 
803  
Hospi[INVESTIGATOR_18552].  
Urgent Cardiology consult 
to establish etiology and 
rule-out immune-mediated 
myocarditis, consider  
myocardial biopsy;  
management o 
Troponin and BNP o 
ECG +/- continuous 
cardiac monitoring o 
Echocardiogram  
o Cardiac MRI  
  
Prompt initiation of 2 
mg/kg/day  
methylprednisolone IV or 
equivalent  
  If symptoms improve and 
immune-mediated etiology is 
ruled out, resume nivolumab and 
N-803.   
  
If worsens, intensify treatment 
according to grade  
• Upon recovery, taper steroids 
over at least 1 month with 
close monitoring of troponin 
and BNP as well as for new 
symptoms  
• Repeat cardiac MRI for post 
treatment assessment and  
cardiology follow- up  
• Retreatment may be 
considered after recovery and 
completion of steroid taper   
Grade 3 or Grade 4  Permanently discontinue 
nivolumab and N-803 
Hospi[INVESTIGATOR_675115]:  
• Troponin and BNP 
monitoring  
• ECG +/- continuous 
cardiac monitoring  
• Echocardiogram  
• Cardiac MRI  
• Myocardial biopsy if 
feasible  
  
• Immediate initiation of 
2 mg/kg/day  
methylprednisolone IV or  
1 g IV bolus  
• Consider adding a second  Once improving, taper steroids 
over at least 1 month  with close 
monitoring of troponin and BNP  
as well as for new symptoms  
  
If no improvement or worsening, 
consider additional 
immunosuppressants (e.g. 
azathioprine, cyclosporine A)  
  
Repeat cardiac MRI for post 
treatment assessments and 
cardiology follow- up  
 
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 38 of 79   CPRC #2017LS116  Suspi[INVESTIGATOR_470490] (e.g. 
severe dehydration, 
hypotension, shock 
out of proportion to 
current illness   Delay or Permanently 
discontinue nivolumab and N803  
Rule out sepsis  
Stress dose of IV steroids 
with mineralocorticoid activity 
IV fluids  
Consult endocrinologist  
If adrenal crisis ruled out, then 
treat as above for 
symptomatic endocrinopathy    
      
      
  
  
  
  
Nivolumab may induce graft versus host disease in patients who have had a prio r 
allogeneic hematopoietic stem cell transplant. To reduce this risk, patients who 
have undergone a prior alloHSCT will receive a lower dose of nivolumab (180 
mg instead of 360 mg).  
  
Complications of allogeneic hematopoietic stem cell transplantation after 
nivolumab have been seen including severe or refractory graft versus host 
disease, hyper-acute GVHD, steroid requiring febrile syndrome without an 
identified infectious cause, encephalitis, and hepatic veno-occlusive disease. 
The consent contains language instructing the participant to inform the tr ansplant 
team of previous nivolumab treatment if he/she undergoes a HSCT at any tim e 
in the future.   
 7.[ADDRESS_912477] institutional guidelines.   
  
For Grade 2 or greater GI toxicities assessed as likely attributable to CTX, drug 
may be held for up to 2 weeks and restarted after improvement of symptoms.  
  
For neutropenic fever with ANC <500 cells/mm3, drug may be held for up to 2 
weeks and restarted as assessed as clinically appropriate by [CONTACT_30780].   
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 39 of 79   CPRC #2017LS116   7.3  N- 803  
Hypotension (systolic blood pressure < 90 mm Hg)  
N-803 dosing should be held for hypotension (defined as systolic blood pres sure 
less than 90 mm Hg) if in the presence of any clinically significant symptoms (in 
the opi[INVESTIGATOR_021]), until the systolic blood pressure reading is 
stable. If mild dehydration is suspected, an IV fluid bolus may be used per 
standard of care.  
  
Based on current experience, localized skin rashes are common with 
subcutaneous administration. If a rash occurs and the rash area surrounding th e 
N-803 injection site is > 6 cm and symptomatic (painful and/or itchy), it may be  
treated (at the discretion of the treating physician) with topi[INVESTIGATOR_2855] 0.05% clobetasol 
propi[INVESTIGATOR_16847] (i.e. 0.05% Cormax) or 0.1% triamcinolone (i.e., Kenalog) cream. 
Diphenhydramine may be administered pre- (25-50 mg TID orally) and 
postdosing (25-50 mg TID orally x 2 days) of N-803 at the discretion of the  
treating physician. Diphenhydramine should be eliminated if not tolerated.  
 8  Schedule of Tests and Procedures  
Scheduled evaluations through during treatment may be performed ±3  days from the 
targeted date. The end of treatment visit may be performed ±[ADDRESS_912478] of care testing as no visit is done solely 
for research. Targeted days may be altered as clinically appropriate.  
     
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 40 of 79   CPRC #2017LS116   8.1  Required Clinical Care Evaluations    
  
Evaluations/Tests 
and Procedures  Baseline (within 
14 days of study 
registration)  During each treatment cycle (up to 5 cycles)  Final Treatment  
Visit ([ADDRESS_912479] 
treatment)    Follow- up 
from C1D1  Day 11  Day 8  Day 15  
Consent   X            
Medical History  X            
Physical Exam  X  X      X    
Weight  X  X    X      
Brief Provider  
Assessment1    X  X  X      
ECOG PS  X            
Adverse Event 
Assessment  
including targeted 
toxicities    X  X  X  X    
CBC, diff, plt  X  X  X  X  X    
Complete metabolic 
panel (CMP)  X  X  X  X  X    
Pregnancy test for  
WOCBP2  X            
Bone Marrow  
Biopsy and  
Aspi[INVESTIGATOR_337]  X4  Prior to cycle 
[ADDRESS_912480] scan 
(extramedullary 
disease only)   X  Prior to cycle 
3 and 5      
    
Survival (PFS and 
OS) by [CONTACT_597706]          
  X (through 2 
years)  
Nivolumab IV 
(charge to 
research)    X    
      
Cyclophosphamide 
PO (charge to 
research)3    X  X  X      
Cyclophosphamide 
drug diary and 
reconciliation    X      X    
N-803 SC (charge 
to research)    X          
N-803 Skin Rash  
Diary   X  X      X    
1 – include assessment for infection and bleeding  
2 – women of child bearing potential must have a negative preg nancy test (serum or urine) within 7 days of each cycle d ay 1 3 
 -- cyclophosphamide administration per patient’s assigned regimen (daily vs weekly)  
  
  
    
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 41 of 79   CPRC #2017LS116  8.2 Research Related Evaluations  
  
  
  Screen  Weekly   Cycle 1   
    Cycle 2   Cycle 3 
D1  Cycle 4 
D1  Cycle 5 
D1  Final  
Treatment  
Visit  
D1  D8  D15  D1  D8  D15  
Assessment of 
immune related 
AEs    X                    X6  
TSH (to FV lab)  X          X            X  
Bone Marrow  
Aspi[INVESTIGATOR_337] (20 
mL 
heparinized 
sample syringe 
or divided into 
4 green top 
tubes, 2 x 2 
mL tubes (4 
mL) in  
Qiagen  
Paxgene  
syringe) at time 
of SOC BM bx5    
X    
      
  
X      
  
  
  
  
  
    
  
  
  
  
  
X      
  
  
  
  
  
X    
  
Peripheral  
Blood (40 mL 
heparinized 
serum divided 
into 3 heparin 
green top 
tubes and 1 
red top tube)  X    
X  X  X  X    
  
  
  
  
X    
  
  
  
  
X    
  
  
  
  
X    
  
  
  
  
X    
  
  
  
  
X  X  
  
4 – Bone Marrow Biopsies may be omitted if not medically safe to perform. If so, peripheral blood counts will be used for 
disease assessment. Baseline bone marrow biopsy may be within [ADDRESS_912481] of care, research aspi[INVESTIGATOR_675116]   
  
6 – BMS requires SAE reporting for [ADDRESS_912482] dose o f nivolumab per Section 11.4 .  
  
All research samples are submitted to TTL unless otherwise noted.  
  
Note: if a patient is not abiding by [CONTACT_134220] ( Section 
8.1), the collection schedule of the toxicity data and research related samples 
may be altered or discontinued on an individual patient basis, as appropriate.    
  
Research related testing on the bone marrow aspi[INVESTIGATOR_675117] T-cell and NK cell subsets by [CONTACT_675142]. AML blast 
immune checkpoint ligand expression will be evaluated by [CONTACT_4133].  Ge ne 
expression analysis of genes will be performed by [CONTACT_675143] T-cell immune activation  
  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 42 of 79   CPRC #2017LS116  Research related testing on the peripheral blood includes analysis of T-cell and 
NK cell subsets, and myeloid blast immune checkpoint ligand expression by [CONTACT_8315].   
[ADDRESS_912483] unused portions of injectable chemotherapeutic agents that do not c ontain a 
bacteriostatic agent or are prepared with un-preserved diluents (i.e., Sterile Wate r for 
Injection USP or 0.9% Sodium Chloride for Injection USP) within eight hours of vial entry  
to minimize the risk of bacterial contamination. The total administered dose of study 
drug may be rounded up or down within a range of 5% of the actu al calculated dose. 
Drug dosages need not be changed unless the calculated dose changes b y at least 
10%.  
 10.1  Nivolumab  
Nivolumab (Opdivo) is a humanized IgG4 monoclonal antibody to PD-1. Its 
mechanism of action is to block an inhibitory signal that decreases cytotoxicity 
towards malignant cells. Nivolumab was initially FDA-approved in [ADDRESS_912484] not been any 
observed differences in safety and efficacy between nivolumab dose of 3 mg /kg 
and 240 mg every 2 weeks in patients with melanoma, NSCLC, and RCC.   
Availability    
Cartons containing 5 vials of 100 mg, 10 mg/mL Nivolumab will be provided fo r 
the study.   
  
Storage and Stability    
Nivolumab must be dispensed only from official study sites and to eligible patie nts 
under the supervision of the site investigator. Nivolumab should be stored in a 
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 43 of 79   CPRC #2017LS116  secure area according to local regulations. It is the responsibility of the site 
investigator to ensure that study drug is only dispensed to patients on this stud y.    
Store Nivolumab under refrigeration at 2°C to 8°C (36°F to 46°F). Protect 
nivolumab from light by [CONTACT_319556]. Do not 
freeze.  
  
The product does not contain a preservative. After preparation, store the 
nivolumab infusion either:  
• at room temperature for no more than 8 hours from the time of preparation. 
This includes room temperature storage of the infusion in the IV container a nd 
time for administration of the infusion or  
• under refrigeration at 2°C to 8°C (36°F to 46°F) for no more than 24 hours 
from the time of infusion preparation.  
  
Administration    
Refer to the current Investigator’s Brochure for the most up to date information.  
Nivolumab is to be administered as an intravenous infusion over 30 minutes 
according to institutional practice.   
  
Toxicities  
Refer to the current Investigator’s Brochure for the most up to date information.  
  
The most common (>10%) adverse events reported in patients treated with 
nivolumab are: fatigue, rash, pruritus, diarrhea, nausea, hypothyroidism, loss of 
appetite, constipation, musculoskeletal pain,  peripheral neuropathy, and pyrexia. 
Events reported in 5-10% of subjects included pneumonia, vomiting, abdominal 
pain, hyperthyroidism, headache, dyspnea, ventricular arrhythmia,  nephritis, 
cough, dry mouth, colitis, autoimmune hypothyroidism,  thyroiditis upper 
respi[INVESTIGATOR_319530]. Laboratory abnormalities 
reported in >10% of patients include hypertransaminasaemia (including ALT 
increased, AST increased, Transaminases increased), increased alkaline 
phosphatase,  increased lipase, increased amylase, hyponatremia, and 
hyperkalemia.  
  
As of the most recent Nivolumab Investigator Brochure, (v19) Fulminant type 1 
diabetes mellitus is included as a SAR based on a comprehensive evaluation. 
Fulminant type 1 diabetes mellitus is characterized by [CONTACT_392316]-onset diabetic 
ketoacidosis, low glycated hemoglobin (HbA1c) value, undetectable serum 
Cpeptide, and negative islet-related autoantibodies. Fulminant type 1 diabete s 
mellitus is generally believed to be a sub-type of non-autoimmune d iabetes, but 
some reports show evidence of involvement of autoimmune mechanism in the 
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 44 of 79   CPRC #2017LS116  onset of fulminant type [ADDRESS_912485] which forms cross links in DNA. The active dosing for 
malignant diseases is generally 1 mg/kg to 5 mg/kg PO per day for cytoto xic 
effect. For immunomodulatory effect, CTX has been given most commonly a t 50 
mg PO daily.[ 69]   
Refer to the FDA-approved package insert for oral cyclophosphamide for product  
information, extensive instructions, and a comprehensive list of adverse events.  
Availability    
Oral cyclophosphamide in 25 mg and 50 mg tablets  will be provided for the study.   
  
Storage and Stability    
Store at room temperature at or below 77 degrees F (25 degrees C) away from 
light and moisture. Brief storage not exceeding 86 degrees F (30 degrees C) is 
permitted.   
Unopened vials of cyclophosphamide are stable until the date indicated on the 
package when stored at or below 25°C (77°F).  
Administration    
Oral, cannot be crushed   
 10.3  N-803 Formulation, Supply, and Potential Toxicity  
  
N-803 (previously known as ALT-803), a recombinant human superagonist IL- 15 
complex, is the working name [CONTACT_625264]. Its active ingredient 
is N-803 and its pharmacologic class is an anti-cancer and anti-viral 
immunotherapeutic.  
  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 45 of 79   CPRC #2017LS116  N-803 has been referred to as IL-15N72D:IL- 15RαSu/IgG1 Fc complex in various 
preclinical study reports, publications, and other related documents.   
10.3.[ADDRESS_912486], N-803, is formulated in a phosphate buffered saline 
(PBS) solution. The solution appears as a clear and colorless liquid. The drug  
substance is produced by a recombinant mammalian cell line and is 
manufactured using a protein free media. The vialed quantitative composition of 
N-803 is listed in the table below.  
  
Quantitative Composition of N-803   
Componenta  Concentration  Amount/Vial  
N-803   1.0 mg/mL  0.6 mg  
N-803  2.0 mg/mL  1.2 mg  
PBS b  QS  0.6 mLc  
  
a – N-803 is available in 2 different concentrations. The volume of PBS used is the same for both. 
b- PBS Formulation: Sodium Chloride (USP) 8.18 g/L; Sodium Phospha te Dibasic (USP) 2.68 
g/L; Potassium Phosphate Monobasic (NF) 1.36 g/L pH 7.4. c - Fill volume is 0.6 mL, extractable 
volume is 0.5mL.  
10.3.2 Structural Formula    
N-803 is a soluble complex consisting of 2 protein subunits of a human IL-15 
variant associated with high affinity to a dimeric IL-15R sushi domain/hum an 
IgG1 Fc fusion protein. The IL-15 variant is a 114 aa polypeptide comprising the 
mature human IL-15 cytokine sequence with an Asn to Asp substitution at 
position 72 of helix C (N72D).6. The human IL-15R sushi domain/human IgG1  
Fc fusion protein comprises the sushi domain of the IL-15R subunit (aa 1-6 5 of 
the mature human IL- 15Rα protein) linked with the human IgG1 CH2 -CH3 region 
containing the Fc domain (232 amino acids). Aside from the N72D substitution, 
all of the protein sequences are human. Based on the amino acid seq uence of 
the subunits, calculated molecular weight of the complex comprising 2 IL15N72D 
polypeptides and a disulfide linked homodimeric IL- 15RαSu/IgG1 Fc protein is 
92.4 kDa. Each IL-15N72D polypeptide has a calculated molecular weight of 
approximately 12.8 kDa and the IL- 15RαSu/IgG1 Fc fusion pro tein has a 
calculated molecular weight of approximately 33.4 kDa. Both the IL-15N72D and  
IL-15RαSu/IgG1 Fc proteins are glycosylated resulting in an apparent molecular 
weight of N-803 as approximately 114 kDa by [CONTACT_115571]. 
The isoelectric point (pI) determined for N-803 range from approximately 5.6 to 
6.5. Thus, the fusion protein is negatively charged at pH 7. The calculated molar 
extinction coefficient at A280 for N-803 is 116,540 M-1, or 1.26 OD280  for a 1 
mg/mL solution of N-803, or one OD280 is equivalent to 0.79 mg/mL  solution of 
N-803.  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 46 of 79   CPRC #2017LS116  10.3.3 Storage and Handling  
N-803 is supplied in a 2-mL single-dose/single-use vial containing 0.6 mL of N803 
(extractable volume is 0.5 mL) at a concentration of 1 mg/mL or 2 mg/mL. Vials  
are packaged in cartons and shipped to the clinical site. Study medication m ust 
be maintained at a temperature between 2°C and 8°C.  
10.3.4 Study Drug Preparation and Administration   
N-803 dose calculation will be based on actual body weight; however fo r patients 
> 100 kilograms weight, the N-803 dose will be calculated using a we ight capped 
at 100 kg. Refer to Section 6.1.4  for additional details.   
  
The calculated amount of N-803 will be drawn into a syringe for subcutane ous 
injection. The current IDS stock concentration is 1 mg/ml. Doses will be drawn 
directly into the syringe for injection. If the total subcutaneous dose is grea ter 
than 1.5 mL, the dose will be divided into 2-3 subcutaneous injectio ns as needed.  
10.3.5 Agent Inventory Records  
The investigator, or a responsible party designated by [CONTACT_093] (e.g. 
institutional investigational pharmacy), must maintain a record of the inventory 
and disposition of study product using the Study Agent Drug Accountability  
Record.   
10.3.[ADDRESS_912487] common side effects seen in studies with subcutaneous (under the 
skin) injections have been, fever, chills, hypoalbuminemia, and injection site 
reaction, and skin rash, which at times has been widespread. These localized 
skins reactions are common (occurring in more than 50% of patients).   
  
In June 2020 an SAE was filed on a study participant who developed atrial  
fibrillation (a-fib) with no prior history resulting in a hospi[INVESTIGATOR_059]. We identified 
a previous case of a patient who developed a-fib while on treatment from a 
different clinical trial that used N-[ADDRESS_912488] possible that they are related, directly or indirectly. A-fib may be 
indirectly triggered in susceptible patients by [CONTACT_675144]/or use of diuretics for 
fluid retention that can be observed with some N803 regimens. Based on th is 
information, we decided to add the development of a-fib as a possible rare side 
effect from N-803 in the consent form.  
  
Very common   Common   Rare  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 47 of 79   CPRC #2017LS116  • injection site reaction (skin 
rash), which may be large (> 
2 inches), itchy, and/or 
painful  
• fever  
• chills  • anemia  
• change in blood pressure  
• nausea  
• swelling of hands or feet  
• temporary changes in 
routine lab results including 
decreased albumin and  
decreased lymphocytes  
  • flu-like symptoms, including 
headache, muscle, or joint 
pain  
• fatigue  
• decreased appetite  
• diarrhea, vomiting  
• abdominal pain  
• itchy skin and/or skin 
irritation  
• shortness of breath • high 
blood sugar  
(hyperglycemia)  
• changes in electrolytes on 
routine lab work  • inflammatory 
reaction  
• infection including 
upper respi[INVESTIGATOR_42977]  
• atrial fibrillation 
(a-fib) – may be 
asymptomatic, 
but when 
symptoms do 
appear they may 
include irregular 
and often rapid 
heartbeat, 
shortness of 
breath, and  
fatigue  
  
  
Tuberculosis is a potential risk of N-803. One instance of tuberculosis has been 
reported in a participant receiving N-803 in combination with BCG (a live, 
attenuated strain of Mycobacterium bovis) administered into the bladder by  a 
urinary catheter. A causal relationship between N-803, in combination with BCG,  
and tuberculosis infection cannot be definitely ruled out.  
  
Anti-N-[ADDRESS_912489] of anti-N-803 antibody formation on clinical efficacy and safety o f N-803 
is unknown.  
  
Previous editions of the N- 803 Investigator’s Brochure prior to 2019 relied heavily 
on clinical experience with the related cytokine therapeutic Proleukin® 
Interleukin-2 to anticipate potential risks associated with (N-[ADDRESS_912490] been removed from the IB and are  
reflected in this protocol and its consent form.    
  
Refer to the current Investigator Brochure (version 7) for additional information.  
  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 48 of 79   CPRC #2017LS116   10.4  N-803 in Combination with Nivolumab  
The combination of N-803 + nivolumab has been associated with AEs of inje ction 
site reaction, flu-like symptoms, fever, fatigue, nausea, pain, chills, dizziness, 
hypotension, cough, dyspnea, anorexia, constipation, and vomiting.  
11 Adverse Event Monitoring, Documentation and Reporting  
Toxicity and adverse events will be classified and graded according to NCI's 
Common Terminology Criteria for Adverse Events version 4.03 (CTCAE) and 
reported on the schedule below. A copy of the CTCAE v4.03 can be downloa ded 
from the CTEP home page  
(https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010- 06- 
14_QuickReference_8.5x11.pdf)  
The following definitions of adverse events (AEs) and serious adverse events  
(SAEs) will determine whether the event requires expedited reporting via the 
OnCore SAE Report Form in addition to routine documentation in the OnCore A E 
case report form (CRF).   
  
SAE Email Address: [EMAIL_176]   
SAE Facsimile Number: +[PHONE_1161]   
If only limited information is initially available, follow-up reports are requ ired. (Note: 
Follow-up SAE reports should include the same investigator term(s) initially 
reported.)   
  
If an ongoing SAE changes in its intensity or relationship to study drug or if ne w 
information becomes available, a follow-up SAE report should be sen t within 24 
hours to BMS (or designee) using the same procedure used for transmitting  the 
initial SAE report.   
  
All SAEs should be followed to resolution or stabilization.   
  
SAEs should be reported on MedWatch Form 3500A, which can be accessed a t: 
http://www.accessdata.fda.gov/scripts/medwatch/. The website will instruct you 
where to send the SAE forms.  
  
The reporting timeframes for SAEs and other reportable events are located in 
Section 11.3 .  
  
Note:  throu ghout this section the generic term “study drug” refers to the study 
related treatment (nivolumab, N-803, and cyclophosphamide). Adverse event 
monitoring will begin with the 1st dose of study drug.  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 49 of 79   CPRC #2017LS116   11.1  Adverse Event Terminology  
Adverse Event:   Any untoward medical occurrence associated with the use of a 
drug in humans, whether or not considered drug related.  
  
Serious Adverse Event:   An adverse event is considered “serious” if, in the view 
of either the investigator or sponsor, it results in any of the following outcomes:   
• Death  
• A life-threatening adverse event  
• Inpatient hospi[INVESTIGATOR_1081]  
• A persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions  
• A congenital anomaly/birth defect  
• Important medical events that may not result in death, be life-threatening , or 
require hospi[INVESTIGATOR_708], based upon 
appropriate medical judgment, they may jeopardize the patient or subject and  
may require medical or surgical intervention to prevent one of the outcomes 
listed in this definition.   
  
Unexpected Event: An adverse event or suspected adverse reaction is 
considered “unexpected” if it is not listed in the investigator brochure or is not 
listed at the specificity or severity that has been observed; or, if an investigato r 
brochure is not required or available, is not consistent with the risk information  
described in the general investigational plan or elsewhere in the current 
application, as amended.   
  
Attribution of Event:  
• Definite – The AE is clearly related  to the study treatment.  
• Probable – The AE is likely related to the study treatment.  
• Possible – The AE may be related  to the study treatment.  
• Unlikely – The AE is doubtfully related to the study treatment.  
• Unrelated – The AE is clearly NOT related  to the study treatment.  
  
The following definitions are from the Masonic Cancer Center’s Standard 
Operating Procedure (SOP) Deviation Reporting:  
  
Major Deviation: A deviation or violation that impacts the risks and benefits of the 
research; may impact subject safety, affect the integrity of research data and/or 
affect a subject’s willingness to participate in the research. Deviations that place 
a subject at risk, but do not result in harm are considered to be major deviations.    
  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 50 of 79   CPRC #2017LS116  Minor Deviation: A deviation or violation that does not impact subject safety, 
compromise the integrity of research data and/or affect a subject’s willingness to 
participate in the research.  
11.[ADDRESS_912491] dose of the 
study drug through the final treatment visit. For the purposes of this study, 
adverse event documentation will focus on immune related adverse events 
(irAEs). Most commonly affected are the skin (rash/vitiligo/pruritis); the liver 
(hepatitis/rise in liver enzymes); the bowel (diarrhea/colitis), and the endocrine 
system (hypophysitis, thyroiditis, adrenal insufficiency). More rarely, uveitis, 
conjunctivitis, neuropathy, myopathy, and nephritis may occur. In addition, any 
unexpected grade [ADDRESS_912492] possibility related to study 
treatment will be documented.  
  
Patients self-administering oral cyclophosphamide will complete a drug diary to 
document administration and side effects.  
  
At visits through the End of Treatment visit a targeted toxicity worksheet 
(Appendix V ) will be completed to document select expected toxicities associated 
with N-803 as follows:  
• Prior to each planned N-803 injection  
• At the end of dose monitoring period (as described in Section 6.1 .4) with 
±20 minute window for 2 hour monitoring or ±10 minute window for 30 
minute monitoring  
• At the End of Treatment visit  
  
Events that count toward an early stoppi[INVESTIGATOR_1877]:  
The following events may or may not meet the definition of a reportab le event; 
however they will be reported to the University of Minnesota Primary Clinical 
Research Coordinator or designee as counting toward an early study stoppi[INVESTIGATOR_10035] (refer to Section 14). These will be monitored throughout stage 1 of the study 
by [CONTACT_2939].  
• Selected Grade 3 non-hematologic events o diarrhea o colitis o pneumonitis 
o transaminitis o myocarditis  o adrenal insufficiency o rash that does 
resolve to grade ≤2 in 1 week    
o cystitis  
• Any new onset of graft versus host disease   
• Any Grade 4 or 5 non-hematologic adverse event  
• Any adverse events requiring discontinuation of any study drug   
  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 51 of 79   CPRC #2017LS116    
     
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 52 of 79   CPRC #2017LS116  11.3 Required Reporting FDA, IRB, and Masonic Cancer Center’s SAE 
Coordinator  
Agency  Criteria for reporting  Timeframe  Form to 
Use  Submission 
address/fax 
numbers  
U of MN 
IRB  Events requiring prompt reporting including, but not limited to 
unanticipated death of a locally enrolled subject(s); new or 
increased risk; any adverse event  that require a change to the 
protocol or consent form or any protocol deviation that 
resulting in harm. refer to  
http://www.research.umn.edu/irb/guidance/ae.html#.VC7xraI0sh  Within 5 
business 
days of 
event 
discovery  Report 
Form  [EMAIL_2817]   
  
Protocol or Subject Deviations  Per current IRB 
reporting requirements  
FDA  
  Unexpected and fatal or life threatening suspected adverse 
reaction  As soon as 
possible 
but no later 
than 7 
Calendar-  
Days  UMCC  
SAE   Submit as an 
amendment 
to IND with 
copy to BMS  1) Serious and unexpected suspected adverse reaction or 2)  
increased occurrence of serious suspected adverse 
reactions over that listed in the protocol or investigator 
brochure or  
3) findings from other sources (other studies, animal or in vitro  
testing)  As soon as 
possible 
but no later 
than [ADDRESS_912493] a stoppi[INVESTIGATOR_675118]   n/a  
  
In each IND safety report, the sponsor must identify all IND safety reports 
previously submitted to the FDA concerning a similar suspected adverse reaction 
and must analyze the significance of the suspected adverse reaction in light of 
the previous, similar reports or other relevant information.  
  
The SAE Coordinat or will provide the Masonic Cancer Center’s Data and Safety 
Monitoring Council (DSMC) with the SAE in an appropriate format de pending on 
the individual SAE (as reported or in a summary format).  
    
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 53 of 79   CPRC #2017LS116   11.4  Additional BMS Requirements for Nivolumab  
Non-serious Adverse Event Collection and Reporting  
The collection of non-serious AE (AE that is not an SAE) information should begin 
at initiation of study drug. All non-serious adverse events (not only those deem ed 
to be treatment-related) should be collected continuously during the trea tment 
period and for a minimum of [ADDRESS_912494] results that constitute SAEs should be 
documented and reported as such.  
The following laboratory abnormalities should be documented and reporte d 
appropriately:  
• any laboratory test result that is clinically significant or meets the definition 
of an SAE  
• any laboratory abnormality that required the subject to have study drug 
discontinued or interrupted  
• any laboratory abnormality that required the subject to receive specific 
corrective therapy.   
Other Safety Considerations  
Any significant worsening noted during interim or final physical examinations, 
electrocardiograms, x-rays, and any other potential safety assessments, whether  
or not these procedures are required by [CONTACT_760], should also be r ecorded as 
a non-serious or serious AE, as appropriate, and reported accordingly.  
Serious Adverse Events (SAEs)  
BMS requires monitoring for Serious Adverse Events (SAEs) that occur followin g 
the subject’s written consen t to participate in the study through [ADDRESS_912495] regulatory and clinical data using University of Minnesota 
CTSI’s instance of OnCore® (Online Enterprise Research Management 
Environment).   
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 54 of 79   CPRC #2017LS116    
The Oncore database resides on dedicated secure and PHI compliant hardware 
consisting of 3 physical servers: dev, DR, and production. The dev server is 
located in the University of Minnesota (UMN) datacenter (WBOB) and houses six 
database instances (test, train, sandbox, mcc reports, oncdm, and vendor) tha t 
are backed up locally because the data is refreshed from Oncore production data . 
The production server is located in the UMN datacenter (WBOB). All the data 
servers are managed by [CONTACT_146093] – Information Systems 
(AHC-IS) virtual servers which utilize clustered infrastructure to provide real-time 
failover of virtual servers. This real-time clustering is physically limited to the UMN 
data center. All relevant AHC IS procedures related for PHI compliant servers (as 
required by [CONTACT_220969]) apply to Oncore databa ses.  
  
The integrated data will be stored in PHI compliant servers managed by [CONTACT_675145] (CTSI BPIC and MCC CISS). The data will be 
integrated and extracted to researchers through the CTSI Informatics team  and 
will be delivered through secure and compliant mechanisms (e.g. AHC IE data 
shelter, BOX, sftp, etc). If data de-identification is needed, then compliant AHC 
IE data de-identification tools will be used. The informatics team will grant the 
IRB approved study team members access to data.  
  
Additional immune monitoring data about correlative laboratory samples 
generated by [CONTACT_337591] 
(TTL) from the protocol-directed correlative research samples is stored in their  
Laboratory Information Management System (LIMS). The LIMS database 
application is also stored on a production server located in the UMN datacente r 
(WBOB) and is managed by [CONTACT_675146].  
12.2 Case Report Forms  
Participant data will be collected using protocol specific electronic case report 
forms (e-CRF) developed within OnCore based on its library of standardized 
forms. The e- CRF will be approved by [CONTACT_1758]’s Principal Investigator [INVESTIGATOR_134163]. The Primary Clinical Research Coordinator 
or designee will be responsible for registering the patient into OnCore at time  of 
study entry, completing e-CRF based on the patient specific calendar, and 
updating the patient record until patient death or end of required study  
participation.   
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 55 of 79   CPRC #2017LS116   12.3  Data and Safety Monitoring Plan (DSMP)  
The study’s Data and Safety Monitoring Plan will be in compliance wi th the 
University of Minnesota Masonic Cancer Center's Data & Safety Monitoring Plan 
(DSMP), which can be accessed at http://z.umn.edu/dmsp   
  
For the purposes of data and safety monitoring, this study is classified as high 
risk (investigator initiated). Therefore the following requirements will be fulfilled:  
▪ The Masonic Cancer Center Data and Safety Monitoring Council (DSMC) will 
review the study’s progress at least quarterly.  
▪ The PI [INVESTIGATOR_291719] e 
Masonic Cancer Center monitoring services.  
▪ The PI [INVESTIGATOR_220948] 11.3  to the Masonic Cancer Center’s SAE 
Coordinator, the University of Minnesota IRB, and the FDA.   
  
IND Annual Reports  
In accordance with regulation 21 CFR § 312.33, the Sponsor-Investigato r will 
submit a progress report annually. The report will be submitted within [ADDRESS_912496].   
 12.4  Monitoring  
The IND sponsor/investigator will permit study-related monitoring, audits, and 
inspections by [CONTACT_229473], IRB, government 
regulatory bodies, and University of Minnesota compliance groups. All study 
related documents (e.g. source documents, regulatory documents, data 
collection instruments, study data, etc.) will be made available. The S/I will  
ensure the capability for inspections of applicable study-related facilities (e.g. 
pharmacy, diagnostic laboratory, etc.) will be available for trial related monito ring, 
audits, or regulatory inspections.  
 12.[ADDRESS_912497] 6 years after the study file is closed with  the IRB 
and FDA.   
  
In addition, the Clinical Trials Office (CTO) will keep a master log of all patients 
participating in the study with sufficient information to allow retrieval of t he 
medical records for that patient.   
  
Please contact [CONTACT_102676].  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 56 of 79   CPRC #2017LS116  13 Endpoints   
Primary endpoint :   
Secondary endpoints :   
Overall response rate (ORR) at 42 days from start of treatment defined as:  
• ORR = [# CR/PR/HI for MDS] + [# CR + CRi + CRp + PR for AML] at day 42  
divided by [CONTACT_675147] ( Appendix II  – R-IPSS  
Criteria for MDS, Appendix III  – Modified Response Criteria for AML)  
  
Progression free survival (PFS) at 6 months  
• PFS is defined as the time (in months) from treatment start date to th e date of 
progression or death, whichever occurs first. Patients who do not progress nor 
die will be censored on their last tumor assessment date. Patients who have no 
post-treatment tumor assessment, will be censored on their treatment sta rt 
date.  
6-month PFS rate will be estimated using the Kaplan-Meier method.   
  
Overall survival (OS) at 6 months   
• OS is defined as the time (in months) from treatment start date to d eath date. 
Patients who do not die will be censored on their last known alive date. [ADDRESS_912498] of relapsed/refractory AML and 
higher-risk MDS.   
  
The primary endpoint of the trial is to determine the appropriate dosing arm for 
phase 2 study based on safety and toxicity profile. The secondary endp oints 
include ORR at day 42, OS at six months and PFS at six months. Exploratory 
endpoints include correlation of immune checkpoint ligands PD-L1 and  TIM-3 on 
leukemic cells with response to treatment, and evaluation of subsets of T-cell,  
NK cell, MDSCs, and DCs in bone marrow and peripheral blood during treatme nt.    
  
By [CONTACT_933] 2019, there were 12 patients enrolled on Arm 1 and Arm 2 who 
received treatment with combination of nivolumab and cyclophosphamide da ily 
or weekly. The previous treatment Arms 1 and 2 are closed due to no patients 
obtaining complete response and 4 patients receiving <1 cycle of treatm ent due 
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 57 of 79   CPRC #2017LS116  to disease progression. These 12 subjects in Arms 1 and 2 will be analyzed 
separately for safety and efficacy from Arms 3 and 4.    
  
Arms 3 and 4 will enroll 20 patients with addition of N-803 to trea tment plan. 
Patients will be randomized to Arm 3 (CTX 50mg daily + nivolumab 360 mg  
q3week + SC N-803 10 ug/kg q3week) and Arm 4 (CTX 350 mg PO q7 da ys+ 
nivolumab 360 mg q3week + SC N-803 10 ug/kg q3week) with [ADDRESS_912499] reduction, and immunological parameters. Immune 
stimulation will be assessed as decrease in T-regulatory cells and MDSCs, and 
increase in cytotoxic T-cells and differentiated NK cells.   
  
  
1. A randomized comparison of two CTX treatments (CTX 50mg daily + 
nivolumab 360 mg q3week + N-803 10 ug/kg SC q3week vs. CTX 350 mg 
PO q7 days+ nivolumab 360 mg q3week + N-803 10 ug/kg SC q3week) using 
10 patients in each Arm.  
2. 20 patients available for assessment of day 42 overall response for the entire 
study population.   
14.2 Data Analysis Plan  
Only subjects enrolled after addition of N-803 to treatment protocol will be 
included in the data analysis. The endpoints of OR and toxicity rate will be 
estimated by [CONTACT_675148] 95% confidence intervals. All toxicity and 
safety assessments will be presented in the data listings and summarized with  
descriptive statistics.  
  
The endpoints of overall survival (OS) and progression-free survival (PFS) at six 
months will be estimated by [CONTACT_5263]-Meier curves. [70] Other correlative 
endpoints will be described with simple descriptive statistics such as medians, 
ranges, interquartile ranges, proportions, charts and plots. Logistic regression 
will be the primary method to compare the PD-L1 and Galectin-9 e xpression with 
response.   
  
Groups that will be considered for comparison include: AML vs. MDS, high vs. 
low blast count at time of study enrollment, high, intermediate, or low disease ri sk 
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 58 of 79   CPRC #2017LS116  by [CONTACT_675149], high vs. low total peripheral lymphocyte 
count, high vs. low immune cell subsets in blood and bone marrow at tim e of 
study enrollment, younger vs. older age, number of prior treatments, high vs.  low 
PD-L1 expression, and prior transplant vs. no transplant.   
  
P-values for subgroup analyses will be adjusted for multiplicity.   
  
All analyses will be conducted using SAS software 9.4 (SAS Institute Inc., Cary, 
NC). Results will be deemed statistically significant at the 0.05 significance 
level unless otherwise specified.  
14.3 Sample Size Justification   
This phase I study for the secondary endpoint of overall response uses pooled 
efficacy analysis. Based on this design, patients from both arms will be analyzed 
for efficacy analysis. Up to 20 patients will be used which is sufficient to m aintain 
an overall type I error of 5%  while providing 80% statistical power. The maximum 
number of the patients will be 20 and the minimum number of patie nts will be 18 
to maintain statistical power of 77% if patients become unevaluable or withdraw 
from study.   
  
Sample Size  Power  
18  77%  
20  80%  
24  85%  
  
This is based on our null hypothesis of ≤10% ORR versus the alternative 
hypothesis of ORR ≥32%.   
  
The accrual will start after amendment to add N-803 to treatment protocol is 
implemented. The 12 patients enrolled by [CONTACT_933] 2019 treated with out N803 
will be analyzed separately.  A patient will be considered unevaluable for t he 
primary endpoint and replaced if unable to complete ≥1 cycle of nivolumab a nd 
cyclophosphamide. If patient receives ≥1 cycle of n ivolumab and 
cyclophosphamide and follow up is not discontinued prior to 42 days for reason s 
other than progression or death, they will be considered evaluable.   
  
ORR will be analyzed using the evaluable patient population.   
PFS and OS will be analyzed using the all treated patient population.   
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 59 of 79   CPRC #2017LS116  14.[ADDRESS_912500] to stop the study in case there are 
excessive complications. In the case that the boundaries are crossed, the 
Principal Investigator [INVESTIGATOR_675119]. The 
protocol will be reviewed to determine if the protocol should be terminat ed. 
Stoppi[INVESTIGATOR_640963]. [71] The 
stoppi[INVESTIGATOR_675120].   
  
Early stoppi[INVESTIGATOR_675121] N-[ADDRESS_912501] a boundary based on selected Grade 3 non-he matologic 
events that result in the permanent discontinuation of study drugs, new onset of 
GVHD, and grade 4-5 non-hematologic toxicities (CTCAE v4.03) such that the  
probability of early stoppi[INVESTIGATOR_429759] 10% if the toxicity rate is equal to 15% and  
our sample size is 10. With these stipulations, the study will be stopped if there 
are events in 2 out of 2, 3 out of 6, 4 at any time within a 60 day follow- up time 
period. If the actual probability of failure is 40% or 50%, the probability o f reaching 
the boundary will be 66% or 85%. The stoppi[INVESTIGATOR_466438] t o Arm 3 and 
4 separately.   
  
15 Ethical and Regulatory Considerations  
 15.1  Good Clinical Practice  
The study will be conducted in accordance with the appropriate regulat ory 
requirement(s). Essential clinical documents will be maintained to demonstrate 
the validity of the study and the integrity of the data collected. Maste r files should 
be established at the beginning of the study, maintained for the d uration of the 
study and retained according to the appropriate regulations.   
 15.[ADDRESS_912502] the rights, safety and well-being of the p atients. The study 
will only be conducted at sites where IRB approval has been obtained. The 
protocol, informed consent, written information given to the patients, safety 
updates, annual progress reports, and any revisions to these documents will  be 
provided to the IRB by [CONTACT_093].   
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 60 of 79   CPRC #2017LS116  15.3 Informed Consent  
All potential study participants will be given a copy of the IRB-approved Conse nt 
to review. The investigator or designee will explain all aspects of the study in lay 
language and answer all questions regarding the study. If the participant d ecides 
to participate in the study, he/she will be asked to sign and date the c onsent 
document. Patients who refuse to participate or who withdraw from the study will 
be treated without prejudice.  
  
16 References  
[1] Mroźek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, et al. 
Prognostic significance of the European LeukemiaNet standardized system for 
reporting cytogenetic and molecular alterations in adults with acute myeloid 
leukemia. J Clin Oncol 2012;30:4515 –23. doi:10.1200/JCO.2012.43.4738.  
[2] Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant 
A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N 
Engl J Med 2009;361:1235 –48. doi:10.1056/NEJMoa0901409.  
[3] Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, et al. Salvage 
chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy 
comparison between CLAG and MEC regimens. Leuk Res 2011;35:301 –4. 
doi:10.1016/j.leukres.2010.09.002.  
[4] Greenberg P, Tuechler H. Revised international prognostic scoring system for 
myelodysplastic syndromes. Blood 2012;120:2454 –65. doi:10.1182/blood-
201203-420489.The.  
[5] Shenghui Z, Yixiang H, Jianbo W, Kang Y, Laixi B, Yan Z, et al. Elevated 
frequencies of CD4+CD25+CD127lo regulatory T cells is associated to poor 
prognosis in patients with acute myeloid leukemia. Int J Cancer 2011;129:1373 – 
81. doi:10.1002/ijc.[ZIP_CODE].  
[6] Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, 
et al. Increased frequency and suppression by [CONTACT_30962] T cells in patients with 
acute myelogenous leukemia. Clin Cancer Res 2009;15:3325 –32.  
doi:10.1158/1078-0432.CCR- 08-3010.  
[7] Kittang AO, Kordasti S, Sand KE, Costantini B, Kramer AM, Perezabellan P, et 
al. Expansion of myeloid derived suppressor cells correlates with number of T 
regulatory cells and disease progression in myelodysplastic syndrome.  
Oncoimmunology 2016;5:e1062208. doi:10.1080/2162402X.2015.106 2208.  
[8] Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R, et al. 
Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis 
have abnormal phenotype and genotype and form defective immune synapse s 
with AML blasts. Blood 2009;114:3909 –16. doi:blood-2009- 02-206946 
[pii]\r10.1182/blood-2009- 02-206946.  
[9] Verheyden S, Demanet C. NK cell receptors and their ligands in leukemia. Leuk  
Off J Leuk Soc Am Leuk Res Fund, [LOCATION_006] 2008;22:249 –57.  
doi:10.1038/sj.leu.2405040.  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 61 of 79   CPRC #2017LS116  [10] Boussiotis VA. Molecular and Biochemical Aspects of the PD-[ADDRESS_912503]. N Engl J Med 2016;375:1767 –78. doi:10.1056/NEJMra1514296.  
[11] Robert C, Long G V, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in 
previously untreated melanoma without BRAF mutation. N Engl J Med 
2015;372:320 –30. doi:10.1056/NEJMoa1412082.  
[12] Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et 
al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell 
Lung Cancer. N Engl J Med 2015;373:123 –35. doi:10.1056/NEJMoa1504627.  
[13] Borghaei H, Paz-Ares L, Horn L, Spi[INVESTIGATOR_43942], Steins M, Ready NE, et al. 
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung 
Cancer. N Engl J Med 2015;373:1627 –39. doi:10.1056/NEJMoa1507643.  
[14] Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et 
al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J 
Med 2015;373:1803 –13. doi:10.1056/NEJMoa1510665.  
[15] Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. 
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N 
Engl J Med 2016;375:1856 –67. doi:10.1056/NEJMoa1602252.  
[16] El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. 
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 
040): an open-label, non-comparative, phase 1/2 dose escalation and expan sion 
trial. Lancet (London, England) 2017;389:2492 –502.  
doi:10.1016/S0140-6736(17)[ZIP_CODE]-2.  
[17] Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. 
Safety profile of nivolumab monotherapy: A pooled analysis of patients with 
advanced melanoma. J Clin Oncol 2017;35:785 –92.  
doi:10.1200/JCO.2015.66.1389.  
[18] Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, et 
al. PD-[ADDRESS_912504] allogeneic hematopoietic cell 
transplant: high response rate but frequent GVHD. Blood 2017;130:blood-
201701-761346. doi:10.1182/blood-2017- 01-761346.  
[19] Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, McSweeney P, et al. 
Optimizing Checkpoint Blockade As a Treatment for Relapsed Hematologic 
Malignancies after Allogeneic Hematopoietic Cell Transplantation. Blood 
2017;130:275 LP-275.  
[20] Chen X, Liu S, Wang L, Zhang W-G, Ji Y, Ma X. Clinical significance of B7- H1（ 
PD-L1）expression in human acute leukemia. Cancer Biol Ther 2008;7:622 –7. 
doi:10.4161/cbt.7.5.5689.  
[21] Salih HR, Wintterle S, Krusch M, Kroner A, Huang YH, Chen L, et al. The role  of 
leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp 
Hematol 2006;34:888 –94. doi:10.1016/j.exphem.2006.03.006.  
[22] Sehgal A, Whiteside TL, Boyiadzis M. Programmed death-1 checkpoint 
blockade in acute myeloid leukemia. Expert Opin Biol Ther 2015;15:1191 –203. 
doi:10.1517/14712598.2015.1051028.  
[23] Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R, 
et al. T cells are functionally not impaired in AML: increased PD-1 expression is 
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 62 of 79   CPRC #2017LS116  only seen at time of relapse and correlates with a shift towards the memory T 
cell compartment. J Hematol Oncol 2015;8:93. doi:10.1186/s13045-015-01 89-2.  
[24] Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, et al. Program 
death-1 (PD-1) signaling and regulatory T cells (Tregs) collaborate to resist the 
function of adoptively transferred cytotoxic T lymphocytes (CTLs) in advanced 
acute myeloid leukemia (AML). Blood 2010;116:2484 –93. 
doi:10.1182/blood2010- 03-275446.  
[25] Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et 
al. PD-L1 regulates the development, maintenance, and function of induced 
regulatory T cells. J Exp Med 2009;206:3015 –29. doi:10.1084/jem.20090847. 
[26] Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. 
Phase i safety and pharmacokinetic study of CT-011, a humanized antibody 
interacting with PD-1, in patients with advanced hematologic malignancies. Clin 
Cancer Res 2008;14:3044 –51. doi:10.1158/1078-0432.CCR- 07-4079.  
[27] Dail M, Yang L, Green C, Ma C, Robert A, Kadel EE  et al. Distinct patterns of 
PD-L1 and PD-L2 expression by [CONTACT_675150]-tumor cells in patients with 
MM,MDS and AML. Blood [Internet] 2016;128:1340.  
[28] Thomas Coats, Alexander e Smith, Thanos P Mourikis, Jonathan Michael Irish 
SK and GJM. Mass Cytometry Reveals PD1 Upregulation Is an Early Step in 
MDS Disease Progression. Blood [Internet] 2016;128:4296.  
[29] Garcia-Manero G, Tallman MS, Martinelli G, Ribrag V, Yang H, Balakumaran A  
et al. Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic 
Syndrome (MDS) after Failure of Hypomethylating Agent Treatment. Blood 
2016;128:345.  
[30] Gonçalves Silva I, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, 
Bardelli M, et al. The Tim-3-galectin-[ADDRESS_912505] is Involved in the 
Immune Escape of Human Acute Myeloid Leukemia Cells. EBioMedicine 
2017;22:44 –57. doi:10.1016/j.ebiom.2017.07.018.  
[31] Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim3 
ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 
2005;6:1245 –52. doi:10.1038/ni1271.  
[32] Gleason MK, Lenvik TR, Mccullar V, Felices M, Brien MSO, Cooley SA, et al. 
Tim-3 is an inducible human natural killer cell receptor that enhances interferon 
gamma production in response to galectin-9 2015;119:3064 –73.  
doi:10.1182/blood-2011- 06-360321.The.  
[33] Li C, Chen X, Yu X, Zhu Y, Ma C, Xia R, et al. Tim-3 is highly expressed in T 
cells in acute myeloid leukemia and associated with clinicopathological  
prognostic stratification 2014;7:6880 –8.  
[34] Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, et al. 
PD1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML 
patients post allogeneic stem cell transplantation. Blood Cancer J 2015;5:e330.  
doi:10.1038/bcj.2015.58.  
[35] Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. 
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype 
in mice with disseminated acute myelogenous leukemia. Blood 2011;117:4501 – 
10. doi:10.1182/blood-2010- 10-310425.  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 63 of 79   CPRC #2017LS116  [36] Folgiero V, Cifaldi L, Li Pi[INVESTIGATOR_20116] G, Goffredo BM, Vinti L, Locatelli F. TIM-3/Gal- [ADDRESS_912506] cells. J Hematol Oncol 2015;8:36. doi:10.1186/s13045-015-0134-4.  
[37] Curti  a, Pandolfi S, Valzasina B, Aluigi M, Isidori  a, Ferri E, et al. Modulation of 
tryptophan catabolism by [CONTACT_675151].  
Blood 2006;109:2871 –8. doi:10.1182/blood-2006- 07-036863.The.  
[38] Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, et al. Tumor 
indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is 
downregulated by [CONTACT_675152]. Blood 2015;125:3905 –16.  
doi:10.1182/blood-2015- 01-621474.  
[39] Curti A, Aluigi M, Pandolfi S, Ferri E, Isidori A, Salvestrini V, et al. Acute myeloid 
leukemia cells constitutively express the immunoregulatory enzyme indoleamine 
2,3-dioxygenase. Leuk 2007;21:353 –5. doi:10.1038/sj.leu.2404485.  
[40] Mabuchi R, Hara T, Matsumoto T, Shibata Y, Nakamura N, Nakamura H, et al. 
High serum concentration of L-kynurenine predicts unfavorable outcomes in 
patients with acute myeloid leukemia. Leuk Lymphoma 2016;57:92 –8.  
doi:10.3109/10428194.2015.1041388.  
[41] Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. 
Metronomic cyclophosphamide regimen selectively depletes CD4 +CD25+ 
regulatory T cells and restores T and NK effector functions in end stage cancer 
patients. Cancer Immunol Immunother 2007;56:641 –8. doi:10.1007/s00262006-
0225-8.  
[42] Lutsiak MEC, Semnani RT, Pascalis R De, Kashmiri SVS, Sabzevari H, Dc W, 
et al. Inhibition of CD4+ 25+ T regulatory cell function implicated in enhanced 
immune response by [CONTACT_6398]-dose cyclophosphamide. Blood 2005;105:2862 –8.  
doi:10.1182/blood-2004- 06-2410.  
[43] Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, et al. 
Cyclophosphamide synergizes with type I interferons through systemic dendritic 
cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 
2011;71:768 –78. doi:10.1158/0008-5472.CAN- 10-2788.  
[44] Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, et al.  
Cyclophosphamide induces differentiation of Th17 cells in cancer patients.  
Cancer Res 2011;71:661 –5. doi:10.1158/0008-5472.CAN- 10-1259.  
[45] Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, et al. Metronomic 
cyclophosphamide treatment in metastasized breast cancer patients: 
Immunological effects and clinical outcome. Cancer Immunol Immunother 
2012;61:353 –62. doi:10.1007/s00262-011-1106-3.  
[46] Lord R, Nair S, Schache A, Spi[INVESTIGATOR_18551] J, Somaihah N, Khoo V, et al. Low Dose  
Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A 
Phase II Study. J Urol 2007;177:2136 –40. doi:10.1016/j.juro.2007.01.143.  
[47] Borne E, Desmedt E, Duhamel A, Mirabel X, Dziwniel V, Maire C, et al. Oral 
metronomic cyclophosphamide in elderly with metastatic melanoma. Invest New 
Drugs 2010;28:684 –9. doi:10.1007/s10637- 009-9298-5.  
[48] Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. Synergistic  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 64 of 79   CPRC #2017LS116  Effect of Metronomic Dosing of Cyclophosphamide Combined with Specific 
Antitumor Immunotherapy in a Murine Melanoma Model. Cancer Res 
2003;63:8408 –13.  
[49] Salem ML, Kadima AN, El-Naggar S a, Rubinstein MP, Chen Y, Gillanders WE, 
et al. Defining the ability of cyclophosphamide preconditioning to enhance the 
antigen-specific CD8+ T-cell response to peptide vaccination: creation of a 
beneficial host microenvironment involving type I IFNs and myeloid cells. J 
Immunother 2007;30:40 –53. doi:10.1097/01.cji.[PHONE_14000].[ZIP_CODE].e3.  
[50] Weir GM, Hrytsenko O, Quinton T, Berinstein NL, Stanford MM, Mansour M. 
Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific 
T cells induced by a potent immune therapy consisting of vaccine and 
metronomic cyclophosphamide. J Immunother Cancer 2016;4:68.  
doi:10.1186/s40425- 016-0169-2.  
[51] Buckstein R, Kerbel RS, Snaked Y, Nayar R, Foden C, Turner R, et al. 
Highdose celecoxib and metronomic “low -dose” cyclophosphamide is an 
effective and safe therapy in patients with relapsed and refractory aggressive 
histology non- Hodgkin’s lymphoma. Clin Cancer Res 2006;12:5190– 8. 
doi:10.1158/10780432.CCR- 06-0474.  
[52] Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system:  
implications for clinical cancer therapy. Cancer Chemother Pharmacol 
2016;78:661 –71. doi:10.1007/s00280-016-3152-1.  
[53] Mpekris F, Baish JW, Stylianopoulos T, Jain RK. Role of vascular normalization 
in benefit from metronomic chemotherapy. Proc Natl Acad Sci U S A 
2017;114:1994 –9. doi:10.1073/pnas.[PHONE_14001].  
[54] Penel N, Adenis A, Bocci G. Cyclophosphamide-based metronomic 
chemotherapy: After 10 years of experience, where do we stand and where are 
we going? Crit Rev Oncol Hematol 2012;82:40 –50.  
doi:10.1016/j.critrevonc.2011.04.009.  
[55] Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in 
patients with acute myeloid leukemia. Blood 2000;95:309 –13.  
[56] Kuzu I, Beksac M, Arat M, Celebi H, Elhan AH, Erekul S. Bone marrow 
microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy 
induced changes and effects on survival. Leuk Lymphoma 2004;45:1185 –90.  
[57] Li K, Yang M, Yuen PMP, Chik KW, Li CK, Shing MMK, et al. Thrombospondin1 
induces apoptosis in primary leukemia and cell lines mediated by [CONTACT_398]36 and 
Caspase-3. Int J Mol Med 2003;12:995 –1001.  
[58] Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immuno l 
Rev 2008;222:357 –68. doi:10.1111/j.1600-065X.2008.[ZIP_CODE].x.  
[59] Sato N, Patel HJ, Waldmann T a, Tagaya Y. The IL-15/IL-15Ralpha on cell 
surfaces enables sustained IL-15 activity and contributes to the long survival of 
CD8 memory T cells. Proc Natl Acad Sci U S A 2007;104:588 –93.  
doi:10.1073/pnas.[PHONE_14002].  
[60] Zhu X, Marcus WD, Xu W, Lee H, Han K, Egan JO, et al. Novel human 
interleukin-15 agonists. J Immunol 2009;183:3598 –607.  
doi:10.4049/jimmunol.0901244.  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 65 of 79   CPRC #2017LS116  [61] Han K, Zhu X, Liu B, Jeng E, Kong L, Yovandich JL, et al. IL-15:IL -[ADDRESS_912507] complex: high-level co-expression in recombinant 
mammalian cells, purification and characterization. Cytokine 2011;56:804 –10. 
doi:10.1016/j.cyto.2011.09.028.  
[62] Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, 
et al. First- in-human Phase [ADDRESS_912508] Complex 
ALT-803 to Treat Relapse after Transplantation. Blood 2018:blood-2017-
12823757. doi:10.1182/blood-2017- 12-823757.  
[63] Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, et al. 
ALT-803, an IL-[ADDRESS_912509], in combination with nivolumab in patients with 
metastatic non-small cell lung cancer: a non-randomised, open-label, pha se 1b 
trial. Lancet Oncol 2018;19:694 –704. doi:10.1016/S1470-2045(18)[ZIP_CODE]-7.  
[64] Voigt P, Reinberg D. Genomic and Epi[INVESTIGATOR_675122]. N Engl 
J Med 2013;368:2059 –74. doi:10.1056/NEJMoa1301689.  
[65] Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ. The 
enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)- 3 
and CD40-ligand. J Exp Med 1997;185:1101 –11. doi:10.1084/jem.185.6.1101. 
[66] Curti A, Trabanelli S, Onofri C, Aluigi M, Salvestrini V, Ocadlikova D, et al. 
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a 
leukemia-specific immune response by [CONTACT_675153] T regulatory cells.  
Haematologica 2010;95:2022 –30. doi:10.3324/haematol.2010.025924.  
[67] Ma L, Delforge M, Duppen V Van, Verhoef G, Emanuel B, Boogaerts M, et al. 
Circulating myeloid and lymphoid precursor dendritic cells are clonally involved 
in myelodysplastic syndromes. Leukemia 2004;18:1451 –6.  
doi:10.1038/sj.leu.2403430.  
[68] Mohty M, Jarrossay D, Lafage-Pochitaloff M, Zandotti C, Brière F, de Lamballeri  
XN, et al. Circulating blood dendritic cells from myeloid leukemia patients display 
quantitative and cytogenetic abnormalities as well as functional impairment. 
Blood 2001;98:3750 –6. doi:10.1182/blood.V98.13.3750.  
[69] Gnoni A, Silvestris N, Licchetta A, Santini D, Scartozzi M, Ria R, et al.  
Metronomic chemotherapy from rationale to clinical studies: A dream or reality?  
Crit Rev Oncol Hematol 2015;95:46 –61. doi:10.1016/j.critrevonc.2015.01.008.  
[70] Kaplan E.L., P M. Nonparametric estimation from incomplete observations. J Am 
Stat Assn 1958;53:457 –81.  
[71] Ivanova A, Qaqish BF, Schell MJ. Continuous toxicity monitoring in phase II 
trials in oncology. Biometrics 2005;61:540 –5. 
doi:10.1111/j.15410420.2005.[ZIP_CODE].x.  
[72] Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al.  
Revised Recommendations of the International Working Group for diagnosis, 
standardization of response criteria, treatment outcomes, and reporting 
standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 
2003;21:4642 –9. doi:10.1200/JCO.2003.04.036.  
[73] Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer 
SD, et al. Clinical application and proposal for modification of the International 
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
 May 12, 2021  Page 66 of 79   CPRC #2017LS116  Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419 – 
25. doi:10.1182/blood-2005- 10-4149.  
  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
May 12, 2021 
 Page 67 of 79   CPRC #2017LS116  Appendix I – ECOG Performance Status   
  
GRADE  ECOG PERFORMANCE STATUS  
0  Fully active, able to carry on all pre-disease performance without restriction  
1  Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature, e.g., light house work, office work  
2  Ambulatory and capable of all selfcare but unable to carry out any work activities; up and 
about more than 50% of waking hours  
3  Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours  
4  Completely disabled; cannot carry on any selfcare; totally confined to bed or chair  
5  Dead  
*Oken M, Creech R, Tormey D, et al. Toxicity and response cr iteria of the Eastern Cooperative Oncology Group. Am J Clin 
Oncol.  1982;5:649-655.   
     
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
May 12, 2021 
 Page 68 of 79   CPRC #2017LS116  Appendix II – Revised International Prognostic Scoring System   
(R-IPSS) Criteria for MDS  
  
Prognostic 
Variable  [ADDRESS_912510] %  ≤ 2%  -  > 2%- < 
5%  -  5%-10%  > 10%  -  
Hemoglobin  ≥ 10  -  8 to 10  <8  -  -  -  
Platelets  ≥ 
100  50- 
<100  < 50  -  -  -  -  
ANC  ≥ 0.8  < 0.8  -  -  -  -  -  
  
  
Cytogenetic Prognostic subgroups   
Very Good  -Y, del(11q)  
Good  Normal, del(5q), del(12p), del(20q), double including del(5q)  
Intermediate  del(7q), +8, +19, i(17q), any other single or double independent clones  
Poor  -7, inv(3)/t(3q)/del(3q), double including -7/del(7q), complex: 3 
abnormalities  
Very poor  Complex:  >3 abnormalities  
  
  
Risk category   Risk score   
Very low   ≤ 1.5  
Low   > 1.5- 3  
Intermediate   > 3-4.5  
High   > 4.5- 6  
Very high   > 6  
  
  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
May 12, 2021 
 Page 69 of 79   CPRC #2017LS116    
  
  
  
  
  
  
  
Appendix III – Response Criteria For MDS and AML  
  
  
Response to treatment will be defined per modified criteria as outlined below. [72][73]   
  
Complete Remission  
For subjects to be classified as being in CR, they must have bone marrow regenerating nor mal hematopoietic 
cells and achieve a morphologic leukemia-free state and must have an ANC > 1 x 109/L and platelet count ≥  
100 x 109/L and normal marrow differential with   
< 5% blasts, and they will be RBC and platelet transfusion independent (defined as 1 wee k without RBC 
transfusion and 1 week without platelet transfusion). There should be no evidence of extrame dullary leukemia.  
  
Complete Remission with Incomplete Platelet Recovery (CRp)  
For subjects to be classified as being in CRp, they must achieve CR except for incomplete pl atelet recovery 
(<100 x 109/L).  
  
Complete Remission with Incomplete Hematologic Recovery (CRi)  
For subjects to be classified as being in CRi, they must fulfill all the criteria for CR except for incomplete 
hematological recovery with residual neutropenia <1 x 109/L with or without complete platelet recovery. RBC 
and platelet transfusion independence is not required.  
  
Partial Remission (PR)  
For subjects to be classified as being in PR, they must have ≥50% bone marrow blast reduction  or decrease to 
5 to 25%.   
  
Hematologic Improvement (HR)   
For subjects to be classified as having HI, they must have pre-treatment hemoglobin of <11 g/dL, platelets of 
<100 x 109/L, and absolute neutrophil count < 1000 cells/mm3. They should have improvement in hemoglobin 
by ≥1.5 g/dL, platelets by ≥30 x 109/L, and neutrophil count by 100% or 500 cells/mm3. Responses should be 
sustained for at least 4 weeks.   
    
Appendix IV – GVHD Grading Scales  
Acute GVHD:  
  
Consensus Clinical Stage and Grade of Acute GVHD (Glucksberg et al, 1974; Thomas et al, 1975, 
Przepi[INVESTIGATOR_20360], 1995)  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
May 12, 2021 
 Page 73 of 79   CPRC #2017LS116  Appendix V - N-803 Targeted Toxicity Worksheet  
MT2017- 33                                                         CTCAE v4            Refer to Section 11.2  for time points    
 Patient Initials:  _______  Date of Assessment:  _________     Assessment Time point:  
_________       
Toxicity  Grade 0  Grade 1  Grade 2  Grade 3  Grade 4  
N-803 Injection 
site reaction  None  Tenderness with or 
without associated 
symptoms (e.g., warmth, 
erythema, itching)  Pain; lipodystrophy; edema; 
phlebitis  Ulceration or necrosis; severe 
tissue damage; operative 
intervention indicated  Life-threatening consequences; 
urgent intervention indicated  
Dyspnea  None or no 
change  Shortness of breath with 
moderate exertion  Shortness of breath with minimal 
exertion; limiting instrumental ADL  Shortness of breath at rest; limiting 
self care ADL  Life-threatening consequences; 
urgent intervention indicated  
Hypoxia  None  ………………  Decreased O 2 saturation with 
exercise (e.g., pulse oximeter < 
88%) intermittent supplemental 
oxygen  Decreased oxygen saturation at 
rest (e.g., pulse oximeter < 88% or 
PaO 2 ≤ 55 mm Hg)  Life-threatening airway 
compromise; urgent intervention 
indicated (e.g., tracheotomy or 
intubation)  
Fever  None  38.0 - 39.0◦ C (100.4 - 
102.2◦ F)  > 39.0 - 40.0◦C (102.3 - 104.0◦F)  > 40.0 ◦ C (>104.0◦ F) for ≤ 24 hrs  > 40.0 ◦ C (>104.0◦ F) for > 24 
hrs  
Chills  None  Mild sensation of cold; 
shivering; chattering of teeth  Moderate tremor of the entire body; 
narcotics indicated  Severe or prolonged, not 
responsive to narcotics  ………………………  
Hypertension  None  Pre-hypertension (systolic 
BP 120 - 139 mm Hg or 
diastolic BP 80 - 89 mm  
Hg)  Stage 1 hypertension (systolic BP  
140 - 159 mm Hg or diastolic BP 90 
99 mm Hg); medical intervention 
indicated; recurrent or persistent ≥ 
24 hrs); symptomatic increase by 
>20 mm Hg (diastolic) or to >140/90 
mm Hg if previously WNL; 
monotherapy indicated.  Stage 2 hypertension (systolic BP 
≥ 160 mm Hg or diastolic BP ≥ 100 
mm Hg); medical intervention 
indicated; more than one drug or 
more intensive therapy than 
previously used indicated.  Life-threatening 
consequences (e.g., malignant 
hypertension, transient or 
permanent neurologic deficit, 
hypertensive crisis); urgent 
intervention indicated.  
Hypotension  None  Asymptomatic, intervention 
not indicated  Non-urgent medical intervention 
indicated  Medical intervention or 
hospi[INVESTIGATOR_80157]-threatening and urgent 
intervention indicated  
Edema  None  Localized to dependent 
areas, no disability or 
functional impairment  Moderate localized edema and 
intervention indicated; limiting 
instrumental ADL  Severe localized edema and  
intervention indicated; limiting self  
care ADL  ………………………  
Pneumonitis  None  Asymptomatic; clinical or 
diagnostic observations 
only; intervention not 
indicated  Symptomatic; medical intervention 
indicated; limiting instrumental 
ADL  Severe symptoms; limiting self care 
ADL; oxygen indicated  Life-threatening respi[INVESTIGATOR_62616]; urgent intervention 
indicated (e.g. intubation or 
tracheotomy)  
Headache  None  Mild pain  Moderate pain; limiting instrumental 
ADL  Severe pain; limiting self care  
ADL  ………………………  
Confusion  
(Altered Mental  
Status)  None  Mild disorientation  Moderate disorientation; limiting 
instrumental ADL  Severe disorientation; limiting self 
care ADL  Life-threatening  consequences; 
urgent intervention indicated  
Rash (outside of 
the injection site 
reaction)  None  Covering < 10% body 
surface area (BSA)  Covering 10-30% body surface area 
(BSA)  >30% body surface area (BSA)  Generalized exfoliative, 
ulcerative, or bullous dermatitis  
Gait Disturbance  None  Mild change in gait (eg, 
wide-based, limpi[INVESTIGATOR_625238])  Moderate change in gait (eg, 
widebased, limpi[INVESTIGATOR_575621]); 
assistance device indicated;  limiting 
instrumental ADL  Disabling; limiting self care ADL  ………………………  
  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
      
May 12, 2021 
 Page 74 of 79   CPRC #2017LS116    
Person Completing Form:              ADL = activities of daily living  
HM2017-33:  Nivolumab, Oral CTX and N-803 in Relapsed/Refractory AML and Higher-Risk MDS  
  
   
Appendix VI – N-[ADDRESS_912511] in formation on page 2 based on the days from that 
injection.   
  
  
For inpatients, the diary is completed by [CONTACT_3462].  
  
HM2017-33:  Nivolumab and Oral CTX in Relapsed/Refractory AML and Higher-Risk MDS    
  
      
May 12, 2021  Page 76 of 79   CPRC #2017LS116        
May 12, 2021  Page 74 of 77  CPRC #2017LS116  
Patient Number*    Date of Study Drug Injection*  ________/_________/________   *To be completed by [CONTACT_39722].   
Please answer all questions below daily for 7 days, beginning with day of treatment. Be sure to bring back this completed dia ry to 
your next clinic visit.  
  
  Instructions  Day of Study  
Drug Injection  
____/____/_________  Day [ADDRESS_912512] Injection  
____/____/_________   Day [ADDRESS_912513] Injection  
____/____/_________  Day [ADDRESS_912514] Injection  
____/____/_________   Day [ADDRESS_912515] Injection  
____/____/________   Day [ADDRESS_912516] Injection  
___/___/________   Day [ADDRESS_912517] Injection  
____/____/_________   
  
1. Is there redness 
at the injection site?  
  Check: Yes  
or No  
If yes, measure longest 
diameter in cm  Yes  No  
  
________cm  Yes  No  
  
________cm  Yes  No   
  
________cm  Yes  No  
  
________cm  Yes  No  
  
________cm  Yes  No  
  
________cm  Yes  No  
  
________cm  
  
2. Is there firmness 
or  
swelling at the 
injection site?   Check:  
Yes  or No  
  Yes  No  
  Yes  No  
  Yes  No  
  Yes  No  
  Yes  No  
  Yes  No  
  Yes  No  
  
  
3. Have you 
experienced any  
pain or itching at 
the injection site?   Check the pain 
and/or itch  
box if present  
And tell us if the pain 
and/or itching is mild, 
moderate or severe   Pain    
Itch  
Mild          Mild  
Mod          Mod  
Severe     Severe    Pain    
Itch  
Mild          Mild  
Mod          Mod  
Severe     Severe    Pain    
Itch  
Mild          Mild  
Mod          Mod  
Severe     Severe    Pain    
Itch  
Mild          Mild  
Mod          Mod  
Severe    Severe    Pain    
Itch  
Mild          Mild  
Mod          Mod  
Severe     Severe    Pain    
Itch  
Mild          Mild  
Mod          Mod  
Severe     Severe    Pain    
Itch  
Mild          Mild  
Mod          Mod  
Severe     Severe   
  
4. Have you taken 
or applied any  
medication for  
injection site pain 
or itching?   Check: Yes  
or No  
Provide name [CONTACT_119311](s)  Yes  No 
Name(s):  
  Yes  No 
Name(s):  
  Yes  No 
Name:  
  Yes  No 
Name:  
  Yes  No 
Name:  
  Yes  No 
Name:  
  Yes  No 
Name:  
  
[CONTACT_511415]2017-33:  Nivolumab and Oral CTX in Relapsed/Refractory AML and Higher-Risk MDS    
  
      
May 12, 2021  Page 78 of 79   CPRC #2017LS116  Page 2 – Please continue to complete for Injection Site Reaction if ongoing after page 1 has been filled out.  
Patient Number*    Date of Study Drug Injection*  ________/_________/________   *To be completed by [CONTACT_39722].   
Complete daily for 7 days or until the injection site has resolved (returned to normal) . Please bring back this completed diary to 
your next clinic visit.  
  
  Instructions  Day [ADDRESS_912518] Injection   
____/____/_________  Day [ADDRESS_912519] Injection  
____/____/_________   Day [ADDRESS_912520] Injection  
____/____/_________  Day [ADDRESS_912521] Injection  
____/____/_________   Day [ADDRESS_912522] Injection  
____/____/________   Day [ADDRESS_912523] Injection  
___/___/________   Day [ADDRESS_912524] Injection  
____/____/_________   
  
1. Is there redness 
at the injection 
site?  
  Check: 
Yes  or No  
If yes, measure longest 
diameter in cm  Yes  No  
  
________cm  Yes  No  
  
________cm  Yes  No   
  
________cm  Yes  No  
  
________cm  Yes  No  
  
________cm  Yes  No  
  
________cm  Yes  No  
  
________cm  
  
2. Is there 
firmness or  
swelling at the 
injection site?   Check:  
Yes  or No  
  Yes  No  
  Yes  No  
  Yes  No  
  Yes  No  
  Yes  No  
  Yes  No  
  Yes  No  
  
  
3. Have you 
experienced any  
pain or itching at 
the injection site?   Check the pain 
and/or itch  
box if present  
And tell us if the pain 
and/or itching is mild, 
moderate or severe   Pain    
Itch  
Mild          Mild  
Mod          Mod  
Severe     Severe    Pain    
Itch  
Mild          Mild  
Mod          Mod  
Severe     Severe    Pain    
Itch  
Mild          Mild  
Mod          Mod  
Severe     Severe    Pain    
Itch  
Mild          Mild  
Mod          Mod  
Severe    Severe    Pain    
Itch  
Mild          Mild  
Mod          Mod  
Severe     Severe    Pain    
Itch  
Mild          Mild  
Mod          Mod  
Severe     Severe    Pain    
Itch  
Mild          Mild  
Mod          Mod  
Severe     Severe   
  
4. Have you taken 
or applied any  
medication for  
injection site pain 
or itching?   Check: 
Yes  or No  
Provide name [CONTACT_119311](s)  Yes  No 
Name(s):  
  Yes  No 
Name(s):  
  Yes  No 
Name:  
  Yes  No 
Name:  
  Yes  No 
Name:  
  Yes  No 
Name:  
  Yes  No 
Name:  
  
[CONTACT_675154] – Noticeable, does not interfere with activity              
Moderate – Interferes with activity, limiting activities of daily living          
Severe – Severely limiting self-care activities of daily living, incapacitating         
HM2017-33:  Nivolumab and Oral CTX in Relapsed/Refractory AML and Higher-Risk MDS    
  
      
May 12, 2021  Page 79 of 79   CPRC #2017LS116    
  